0001023024-24-000102 | 10-Q | XBRL Viewer

Print Document

DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY	9 Months Ended
DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY	DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY In April 2020, the Company entered into an interest rate swap with Citizens Bank, N.A. to manage its exposure to changes in the London Interbank Offered Rate (“LIBOR”)LIBOR-based interest rates underlying total borrowings under term facilities related to the prior credit agreement, and the interest rate swap matures in December 2026. The Company amended its Credit Agreement to transition from LIBOR to the Secured Overnight Financing Rate (“SOFR”) due to the cessation of LIBOR in the third quarter of 2023, and accordingly, the interest rate swap transitioned from LIBOR to SOFR. The interest rate swap is used to manage changes in SOFR-based interest rates underlying a portion of the borrowing under the Term Facility. Concurrent with the termination of the prior credit agreement and entry into the Credit Agreement with Truist Bank, the interest rate swap with a notional value of $168.6 million at origin on November 21, 2021 was novated and Truist Bank became the new counterparty. On August 30, 2024, in connection with the New Credit Facility, the interest rate swap with a notional value of $139.4 million was transferred from Truist Bank to JPMorgan Chase Bank, N.A., as the new counterparty. The interest rate swap is used to manage changes in SOFR-based interest rates underlying a portion of the borrowing under the New Term Facility. The interest rate swap provides an effective fixed interest rate of 2.313% and is designated as an effective cash flow hedge and therefore qualifies for hedge accounting. As of September 30, 2024, the notional amount of the interest rate swap was $139.4 million, and will remain static until maturity in December 2026. As of September 30, 2024, the fair value of the interest rate swap asset recorded in other non-current assets in the unaudited interim condensed consolidated balance sheets is $3.6 million. As of September 30, 2024, $5.6 million was recorded in accumulated other comprehensive (loss) income, net of tax in the unaudited interim condensed consolidated balance sheets. During the three and nine months ended September 30, 2024, the loss on the fair value of the interest rate swaps, net of tax recorded in accumulated other comprehensive (loss) income in the unaudited interim condensed consolidated statements of comprehensive income was approximately $2.8 million and $3.3 million, respectively. Differences between the hedged SOFR rate and the fixed rate are recorded as interest expense in the same period that the related interest is recorded for the Term Facility based on the SOFR rate. In the three and nine months ended September 30, 2024, the Company recorded a reduction in interest expense of $1.7 million and $4.9 million in relation to the interest rate swaps, respectively. In the three and nine months ended September 30, 2023, the Company recorded a reduction in interest expense of $0.7 million and $1.8 million in relation to the interest rate swaps, respectively. Included in this amount for the three and nine months ended September 30, 2024 are reclassifications out of accumulated other comprehensive (loss) income of $0.2 million of interest income and $0.6 million, respectively, related to terminated and de-designated cash flow hedges. Included in this amount for the three and nine months ended September 30, 2023 are reclassifications out of accumulated other comprehensive (loss) income of $0.7 million of interest income and $2.1 million, respectively, related to terminated and de-designated cash flow hedges.

RELATED PARTY TRANSACTIONS

9 Months Ended

Sep. 30, 2024

RELATED PARTY TRANSACTIONS

PIPE Shares

On March 8, 2021, the Company entered into an Equity Commitment and Investment Agreement with the PIPE Investor, pursuant to which 25,000 shares were purchased for $1,000 per share for an aggregate purchase price of $25.0 million on November 19, 2021. The Chairman of the Company’s board of directors is an operating partner of Ampersand Capital Partners, an affiliate of the PIPE Investor.

Novitium

In connection with the acquisition of Novitium, the Company entered into employment agreements with the two executives and founders of Novitium, Muthusamy Shanmugam, Head of R&D and COO of NJ Operations of ANI, and Chad Gassert, Sr. Vice President, Corporate Development and Strategy of ANI. Both serve as executive officers of the Company and Mr. Shanmugam also serves on the Company’s board of directors. Mr. Shanmugam holds a minority interest in Scitus Pharma Services (“Scitus”), which provides clinical research services to Novitium, a majority interest in SS Pharma LLC (“SS Pharma”), which acquires and supplies API to Novitium, a minority interest in Nuray Chemical Private Limited (“Nuray”), which manufactured and supplied API to Novitium in prior periods, a majority interest in Esjay Pharma LLC (“Esjay”), which provides research and development and facilities consulting services, and a minority interest in SThree Chemicals Pvt Ltd (“SThree”), which acquires and supplies API to Novitium.

A summary of payments to related parties is presented below:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Scitus Pharma Services	$	1,155	$	1,322	$	2,236	$	3,227
SS Pharma LLC	—		2,480		1,245		6,059
SThree Chemicals Pvt Ltd	4,214		—		5,283		—
Esjay Pharma LLC	79		—		79		—
	$	5,448	$	3,802	$	8,843	$	9,286

As of September 30, 2024, the outstanding balances due to Scitus, SThree, and Esjay were $0.4 million, $1.6 million, and $14 thousand respectively. There was no outstanding balance due to SS Pharma.

On December 12, 2023, the Company paid $12.5 million of cash consideration to the Company Members of Novitium for the achievement of the “ANDA Filing Earn-Out,” as defined in the Novitium Merger Agreement. The Company paid Mr. Shanmugam and Esjay, and Mr. Gassert’s company Chali Properties LLC, approximately $6.7 million and $1.9 million, respectively, for their portion of the cash consideration due to them as part of the Novitium acquisition.

On February 22, 2024, the Company paid $12.5 million of cash consideration to the Company Members of Novitium for the achievement of the “Gross Profit Earn-Out,” as defined in the Novitium Merger Agreement. The Company paid Mr. Shanmugam and Esjay, and Mr. Gassert’s company Chali Properties LLC, approximately $6.7 million and $1.9 million, respectively, for their portion of the cash consideration due to them as part of the Novitium acquisition.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

TRUIST CREDIT FACILITY - Interest (Details) - Term Facility - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Debt Instrument [Line Items]
Contractual coupon	$ 2,883	$ 7,864	$ 16,644	$ 22,834
Amortization of deferred financing costs	295	591	1,477	1,773
Capitalized interest	138	142	401	440
Total	$ 3,040	$ 8,313	$ 17,720	$ 24,167

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

2.25% CONVERTIBLE SENIOR NOTES - Interest (Details) - Convertible Senior Notes due 2029 - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Debt Instrument [Line Items]
Contractual coupon	$ 969	$ 0	$ 969	$ 0
Amortization of deferred financing costs	281	0	281	0
Total	$ 1,250	$ 0	$ 1,250	$ 0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

FAIR VALUE DISCLOSURES - Narrative (Details)						3 Months Ended	9 Months Ended		12 Months Ended
FAIR VALUE DISCLOSURES - Narrative (Details)	Dec. 31, 2024 USD ($)	Sep. 16, 2024 USD ($) $ / shares	Feb. 22, 2024 USD ($)	Dec. 12, 2023 USD ($)	May 17, 2021 USD ($)	Sep. 30, 2024 USD ($) guarantee	Sep. 30, 2024 USD ($) guarantee	Sep. 30, 2023 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Jan. 24, 2024 shares	Dec. 31, 2023 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money Market Fund						$ 83,304,000	$ 83,304,000					$ 191,841,000
Interest rate swap						3,556,000	$ 3,556,000					6,236,000
Achievement of milestones payment period							24 months
Payments on contingent consideration							$ 12,500,000	$ 0
Contingent consideration, Novitium						12,800,000	12,800,000					24,000,000.0
Novitium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Additional contingent consideration						46,500,000	46,500,000
Payments on contingent consideration			$ 12,500,000	$ 12,500,000
Contingent consideration, Novitium						12,758,000	12,758,000					$ 23,984,000
Alimera Sciences, Inc
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Common Stock, par value (in dollars per share) \| $ / shares		$ 0.01
Business combination, milestone payment multiplier		0.25
Contingent consideration, Novitium						8,700,000	8,700,000
CG Oncology
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Shares held (in shares) \| shares											219,925
Closing price						$ 37.73	$ 37.73
Accrued Licensor Payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Up-front payment					$ 75,000,000
Number of quarterly guaranteed payment \| guarantee						3	3
Additional milestone payment							$ 5,600,000
Fair value of payments						$ 8,300,000	8,300,000
Accrued Licensor Payments \| Forecast
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Additional milestone payment										$ 7,500,000
Collaborative arrangement royalty payable on net revenue revenue threshold									$ 70,000,000
Eye Point Agreements Member
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Payments for royalties						1,900,000
Fair value of payments						23,100,000	23,100,000
Eye Point Agreements Member \| Forecast
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Payments for royalties	$ 1,900,000
Alimera Sciences, Inc \| Contingent Value Rights Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration classified as equity, fair value disclosure						$ 8,700,000	$ 8,700,000
2026 Milestone Revenue Payment \| Alimera Sciences, Inc
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, divisible revenue		$ 10,000,000
2026 Milestone Revenue Payment \| Alimera Sciences, Inc \| Contingent Value Rights Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, milestone payment, revenue achievement		$ 140,000,000.0
Business combination, milestone payment multiplier		0.25
Business combination, divisible revenue		$ 10,000,000
2027 Milestone Revenue Payment \| Alimera Sciences, Inc
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, divisible revenue		15,000,000
2027 Milestone Revenue Payment \| Alimera Sciences, Inc \| Contingent Value Rights Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, milestone payment, revenue achievement		$ 160,000,000.0
Business combination, milestone payment multiplier		0.25
Business combination, divisible revenue		$ 15,000,000
Contingent consideration, milestone payment, CVRs agreement business days		15 days

Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive Income, Net of Tax	Accumulated Deficit	Convertible Preferred Stock
Balance at Dec. 31, 2022							$ 24,850
Balance (in shares) at Dec. 31, 2022							25,000
Balance at Sep. 30, 2023							$ 24,850
Balance (in shares) at Sep. 30, 2023							25,000
Balance at Dec. 31, 2022		$ 1	$ 403,900	$ (5,094)	$ 12,167	$ (97,285)
Beginning Balance, Common (in shares) at Dec. 31, 2022		17,644,000
Beginning Balance, Treasury (in shares) at Dec. 31, 2022				149,000
Beginning balance, permanent and temporary equity at Dec. 31, 2022	$ 338,539
Increase (decrease) in Stockholders' Equity
Stock-based Compensation Expense	15,031		15,031
Treasury Stock Purchases for Restricted Stock Vests (in shares)				111,000
Treasury Stock Purchases for Restricted Stock Vests	(4,756)			$ (4,756)
Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)		170,000
Issuance of Common Shares upon Stock Option and ESPP Exercise	7,027		7,027
Issuance of Restricted Stock Awards (in shares)		648,000
Issuance of Performance Stock Units (in shares)		85,000
Restricted Stock Awards and Performance Stock Units Forfeitures (in shares)		(77,000)
Issuance of Common Stock in Public Offering	80,556	$ 1	80,555
Issuance of Common Stock in Public Offering (in shares)		2,184,000
Dividends on Series A Convertible Preferred Stock	(1,219)					(1,219)
Other Comprehensive Income (Loss)	1,909				1,909
Net Income	17,624					17,624
Balance at Sep. 30, 2023		$ 2	506,513	$ (9,850)	14,076	(80,880)
Ending Balance, Common (in shares) at Sep. 30, 2023		20,654,000
Ending Balance, Treasury (in shares) at Sep. 30, 2023				260,000
Ending balance, permanent and temporary equity at Sep. 30, 2023	454,711
Balance at Jun. 30, 2023							$ 24,850
Balance (in shares) at Jun. 30, 2023							25,000
Balance at Sep. 30, 2023							$ 24,850
Balance (in shares) at Sep. 30, 2023							25,000
Balance at Jun. 30, 2023		$ 2	495,488	$ (9,180)	13,726	(90,414)
Beginning Balance, Common (in shares) at Jun. 30, 2023		20,536,000
Beginning Balance, Treasury (in shares) at Jun. 30, 2023				248,000
Beginning balance, permanent and temporary equity at Jun. 30, 2023	434,472
Increase (decrease) in Stockholders' Equity
Stock-based Compensation Expense	5,444		5,444
Treasury Stock Purchases for Restricted Stock Vests (in shares)				12,000
Treasury Stock Purchases for Restricted Stock Vests	(670)			$ (670)
Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)		125,000
Issuance of Common Shares upon Stock Option and ESPP Exercise	5,581		5,581
Issuance of Restricted Stock Awards (in shares)		24,000
Restricted Stock Awards and Performance Stock Units Forfeitures (in shares)		(31,000)
Dividends on Series A Convertible Preferred Stock	(406)					(406)
Other Comprehensive Income (Loss)	350				350
Net Income	9,940					9,940
Balance at Sep. 30, 2023		$ 2	506,513	$ (9,850)	14,076	(80,880)
Ending Balance, Common (in shares) at Sep. 30, 2023		20,654,000
Ending Balance, Treasury (in shares) at Sep. 30, 2023				260,000
Ending balance, permanent and temporary equity at Sep. 30, 2023	454,711
Balance at Dec. 31, 2023	24,850						$ 24,850
Balance (in shares) at Dec. 31, 2023							25,000
Balance at Sep. 30, 2024	24,850						$ 24,850
Balance (in shares) at Sep. 30, 2024							25,000
Balance at Dec. 31, 2023	$ 432,749	$ 2	514,103	$ (10,081)	8,857	(80,132)
Beginning Balance, Common (in shares) at Dec. 31, 2023		20,731,000
Beginning Balance, Treasury (in shares) at Dec. 31, 2023	263,943			264,000
Beginning balance, permanent and temporary equity at Dec. 31, 2023	$ 457,599
Increase (decrease) in Stockholders' Equity
Stock-based Compensation Expense	22,283		22,283
Capped Call Transaction, net of tax	(30,275)		(30,275)
Treasury Stock Purchases for Restricted Stock Vests (in shares)				160,000
Treasury Stock Purchases for Restricted Stock Vests	(10,641)			$ (10,641)
Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)		80,000
Issuance of Common Shares upon Stock Option and ESPP Exercise	4,788		4,788
Issuance of Restricted Stock Awards (in shares)		669,000
Issuance of Performance Stock Units (in shares)		74,000
Restricted Stock Awards and Performance Stock Units Forfeitures (in shares)		(60,000)
Dividends on Series A Convertible Preferred Stock	(1,219)					(1,219)
Other Comprehensive Income (Loss)	(3,491)				(3,491)
Net Income	(8,246)					(8,246)
Balance at Sep. 30, 2024	$ 405,948	$ 2	510,899	$ (20,722)	5,366	(89,597)
Ending Balance, Common (in shares) at Sep. 30, 2024		21,494,000
Ending Balance, Treasury (in shares) at Sep. 30, 2024	423,936			424,000
Ending balance, permanent and temporary equity at Sep. 30, 2024	$ 430,798
Balance at Jun. 30, 2024							$ 24,850
Balance (in shares) at Jun. 30, 2024							25,000
Balance at Sep. 30, 2024	24,850						$ 24,850
Balance (in shares) at Sep. 30, 2024							25,000
Balance at Jun. 30, 2024		$ 2	532,497	$ (20,042)	8,328	(65,025)
Beginning Balance, Common (in shares) at Jun. 30, 2024		21,476,000
Beginning Balance, Treasury (in shares) at Jun. 30, 2024				413,000
Beginning balance, permanent and temporary equity at Jun. 30, 2024	480,610
Increase (decrease) in Stockholders' Equity
Stock-based Compensation Expense	7,484		7,484
Capped Call Transaction, net of tax	(30,275)		(30,275)
Treasury Stock Purchases for Restricted Stock Vests (in shares)				11,000
Treasury Stock Purchases for Restricted Stock Vests	(680)			$ (680)
Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)		3,000
Issuance of Common Shares upon Stock Option and ESPP Exercise	1,193		1,193
Issuance of Restricted Stock Awards (in shares)		62,000
Restricted Stock Awards and Performance Stock Units Forfeitures (in shares)		(47,000)
Dividends on Series A Convertible Preferred Stock	(406)					(406)
Other Comprehensive Income (Loss)	(2,962)				(2,962)
Net Income	(24,166)					(24,166)
Balance at Sep. 30, 2024	$ 405,948	$ 2	$ 510,899	$ (20,722)	$ 5,366	$ (89,597)
Ending Balance, Common (in shares) at Sep. 30, 2024		21,494,000
Ending Balance, Treasury (in shares) at Sep. 30, 2024	423,936			424,000
Ending balance, permanent and temporary equity at Sep. 30, 2024	$ 430,798

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. As of September 30, 2024, a valuation allowance was recorded against consolidated net deferred tax assets of $0.4 million, related solely to deferred tax assets for net operating loss carryforwards in certain U.S. state jurisdictions. The Company uses a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company has not identified any uncertain income tax positions that could have a material impact on the consolidated financial statements. The Company recognizes interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense; the Company did not have any such amounts accrued as of September 30, 2024 and December 31, 2023. The Company is subject to taxation in various U.S. jurisdictions, Canada, India, the United Kingdom, Ireland, Portugal, and Germany and all of its income tax returns remain subject to examination by tax authorities due to the availability of NOL carryforwards. For interim periods, the Company recognizes an income tax expense (benefit) based on our estimated annual effective tax rate, calculated on a worldwide consolidated basis, expected for the entire year. The interim annual estimated effective tax rate is based on the statutory tax rates then in effect, as adjusted for estimated changes in estimated permanent differences and excludes certain discrete items whose tax effect, when material, are recognized in the interim period in which they occur. These changes in permanent differences and discrete items result in variances to the effective tax rate from period to period. The Company’s estimated annual effective tax rate changes throughout the year as our on-going estimates of pre-tax income, and changes in permanent differences are revised, and as discrete items occur. Global Intangible Low-Taxed Income (“GILTI”), as defined in the Tax Cuts and Jobs Act of 2017, generated from our non-U.S. operations is subject to U.S. taxes, with certain defined exemptions, thresholds and credits. For financial reporting purposes the Company has elected to treat GILTI inclusions as a period cost. For the three months ended September 30, 2024, the Company recognized an income tax benefit of $7.3 million. The Company’s effective tax rate was 23.3% after discrete items for the three months ended September 30, 2024. The effective tax rate differed from the federal statutory rate of 21% primarily due to state taxes, stock based compensation, and non-deductible expenses related to the completed acquisition of Alimera. For the three months ended September 30, 2023, the Company recognized an income tax expense of $1.6 million. The Company’s effective tax rate was 13.6% for the three months ended September 30, 2023. The effective tax rate differed from the federal statutory rate of 21% primarily due to the recognition of the U.S. federal research and development credit, permanent differences, and stock based compensation. For the nine months ended September 30, 2024, the Company recognized an income tax benefit of $0.2 million. The Company’s effective tax rate was 2.4% after discrete items for the nine months ended September 30, 2024. The effective tax rate differed from the federal statutory rate of 21% primarily due to state taxes, stock based compensation, tax on the sale of the Oakville, Ontario manufacturing site, and recording of a withholding tax liability on the proceeds of the sale, and non-deductible expenses related to the completed acquisition of Alimera. For the nine months ended September 30, 2023, the Company recognized an income tax expense of $1.3 million. The Company’s effective tax rate was 6.9% for the nine months ended September 30, 2023. The effective tax rate differed from the federal statutory rate of 21% primarily due to the recognition of the U.S. federal research and development credit, permanent differences, and stock based compensation. The Company does not expect that any law changes enacted during the period will have a material impact on the provision for income taxes.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

NEW CREDIT AGREEMENT - Narrative (Details) - Line of Credit $ in Thousands	Aug. 13, 2024 USD ($)	Aug. 12, 2024	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
New Credit Agreement
Debt Instrument [Line Items]
Deferred debt issuance costs			$ 1,100
Debt issuance costs, noncurrent			3,957	$ 0
Unused capacity commitment fee percentage	0.40%	0.25%
New Credit Agreement \| Other Noncurrent Assets
Debt Instrument [Line Items]
Deferred debt issuance costs			900
New Credit Agreement \| Other Current Assets
Debt Instrument [Line Items]
Deferred debt issuance costs			$ 200
Secured Debt \| New Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 325,000
Secured Debt \| New Credit Agreement \| Prior to One Year, Closing Date
Debt Instrument [Line Items]
Quarterly principal payment, percentage of amount outstanding	0.625%
Secured Debt \| New Credit Agreement \| One Year Anniversary, Closing Date
Debt Instrument [Line Items]
Quarterly principal payment, percentage of amount outstanding	1.25%
Secured Debt \| New Credit Agreement \| Three Year Anniversary, Closing Date
Debt Instrument [Line Items]
Quarterly principal payment, percentage of amount outstanding	1.875%
Secured Debt \| New Term Facility
Debt Instrument [Line Items]
Line of credit facility, effective rate			0.0795
Line of credit facility, interest rate at period end			8.37%
Deferred debt issuance costs	$ 5,000
Revolving Credit Facility \| New Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity	75,000
Debt issuance costs, noncurrent	$ 1,100

EARNINGS PER SHARE (Tables)

9 Months Ended

Sep. 30, 2024

Earnings Per Share [Abstract]

Schedule of earnings per share, basic and diluted

Earnings per share for the three and nine months ended September 30, 2024 and 2023 are calculated for basic and diluted earnings per share as follows:


	Basic				Diluted				Basic				Diluted
(in thousands, except per share amounts)	Three Months Ended September 30,				Three Months Ended September 30,				Nine Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023		2024		2023		2024		2023
Net (loss) income available to common shareholders	$	(24,572)	$	9,534	$	(24,572)	$	9,534	$	(9,465)	$	16,405	$	(9,465)	$	16,405
Earnings allocated to participating securities	—		(891)		—		(881)		—		(1,629)		—		(1,615)
Net (loss) income available to common shareholders	$	(24,572)	$	8,643	$	(24,572)	$	8,653	$	(9,465)	$	14,776	$	(9,465)	$	14,790
Basic Weighted-Average Shares Outstanding	19,404		18,883		19,404		18,883		19,275		17,663		19,275		17,663
Dilutive effect of common stock options, ESPP, and performance stock units					—		242						—		160
Diluted Weighted-Average Shares Outstanding					19,404		19,125						19,275		17,823

(Loss) earnings per share	$	(1.27)	$	0.46	$	(1.27)	$	0.45	$	(0.49)	$	0.84	$	(0.49)	$	0.83

GOODWILL AND INTANGIBLE ASSETS - Components (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Definite-Lived Intangible Assets:
Gross Carrying Amount	$ 897,339	$ 496,708
Accumulated Amortization	(347,314)	(307,499)
Total	$ 550,025	189,209
Remaining Weighted Average Amortization Period	9 years 9 months 18 days
Indefinite-Lived Intangible Assets:
Total Intangible Assets, Gross	$ 917,139	516,508
Total Intangible Assets, Net	569,825	209,009
In process research and development
Indefinite-Lived Intangible Assets:
Gross Carrying Amount	19,800	19,800
Acquired ANDAs intangible assets
Definite-Lived Intangible Assets:
Gross Carrying Amount	210,411	209,780
Accumulated Amortization	(118,804)	(100,660)
Total	$ 91,607	109,120
Remaining Weighted Average Amortization Period	4 years 7 months 6 days
NDAs and product rights
Definite-Lived Intangible Assets:
Gross Carrying Amount	$ 644,871	244,871
Accumulated Amortization	(203,143)	(184,861)
Total	$ 441,728	60,010
Remaining Weighted Average Amortization Period	11 years
Marketing and distribution rights
Definite-Lived Intangible Assets:
Gross Carrying Amount	$ 17,157	17,157
Accumulated Amortization	(14,992)	(14,271)
Total	$ 2,165	2,886
Remaining Weighted Average Amortization Period	2 years 2 months 12 days
Customer relationships
Definite-Lived Intangible Assets:
Gross Carrying Amount	$ 24,900	24,900
Accumulated Amortization	(10,375)	(7,707)
Total	$ 14,525	$ 17,193
Remaining Weighted Average Amortization Period	4 years 1 month 6 days

EARNINGS PER SHARE - Narrative (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares diluted earnings (loss) per share (in shares)	2.7	2.1	2.3	2.4
Convertible Debt Securities
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares diluted earnings (loss) per share (in shares)	4.3		4.3

GOODWILL AND INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

Goodwill

As of September 30, 2024, the Company has two operating segments, which were also deemed the Company’s two reporting units, Generics, Established Brands, and Other reporting unit and the Rare Disease reporting unit. As a result of the 2013 merger with BioSante Pharmaceuticals, Inc., the Company recorded goodwill of $1.8 million. As a result of the acquisition of WellSpring Pharma Services Inc. in 2018, the Company recorded goodwill of $1.7 million. From the acquisition of Novitium in 2021, the Company recorded goodwill of $24.6 million. The goodwill from the transactions with BioSante Pharmaceuticals, Inc., WellSpring Pharma Services Inc., and Novitium is recorded in the Generics, Established Brands, and Other reporting unit. As a result of the acquisition of Alimera, on September 16, 2024, the Company recorded goodwill of $32.2 million in the Rare Disease reporting unit. Refer to Note 3 “Business Combination” to the Notes to Condensed Consolidated Financial Statements for further information related to the acquisition.

Goodwill is reviewed for impairment at least annually, at October 31, or more frequently if a triggering event occurs between impairment testing dates. The Company’s impairment assessment begins with a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. Qualitative factors may include, macroeconomic conditions, industry and market considerations, cost factors, and other relevant entity and Company specific events. If, based on the qualitative test, the Company determines that it is “more likely than not” that the fair value of a reporting unit is less than its carrying value, then we evaluate goodwill for impairment by comparing the fair value of our reporting unit to its respective carrying value, including its goodwill. If it is determined that it is “not likely” that the fair value of the reporting unit is less than its carrying value, then no further testing is required. There have been no events or changes in circumstances that would have reduced the fair value of the Generics, Established Brands, and Other reporting unit or the Rare Disease reporting unit below their carrying value during the three and nine months ended September 30, 2024 and 2023, and as a result no impairment charges have been recognized.

Intangible Assets

The components of definite-lived intangible assets and indefinite-lived intangible assets, other than goodwill, are as follows:


	September 30, 2024						December 31, 2023						Remaining Weighted Average Amortization Period(1)
(in thousands)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Definite-Lived Intangible Assets:
Acquired ANDAs intangible assets	$	210,411	$	(118,804)	$	91,607	$	209,780	$	(100,660)	$	109,120	4.6 years
NDAs and product rights	644,871		(203,143)		441,728		244,871		(184,861)		60,010		11.0 years
Marketing and distribution rights	17,157		(14,992)		2,165		17,157		(14,271)		2,886		2.2 years
Customer relationships	24,900		(10,375)		14,525		24,900		(7,707)		17,193		4.1 years
Total Definite-Lived Intangible Assets	897,339		(347,314)		550,025		496,708		(307,499)		189,209		9.8 years
Indefinite-Lived Intangible Assets:
In process research and development	19,800		—		19,800		19,800		—		19,800		Indefinite
Total Intangible Assets, net	$	917,139	$	(347,314)	$	569,825	$	516,508	$	(307,499)	$	209,009

(1)Weighted average amortization period as of September 30, 2024.

Definite-lived intangible assets arising from business combinations and other asset acquisitions include intangibles such as Abbreviated New Drug Applications (“ANDAs”), New Drug Applications (“NDAs”) and product rights, marketing and distribution rights, customer relationships, and non-compete agreements. Definite-lived intangible assets are amortized over the estimated period during which the asset is expected to contribute directly or indirectly to future cash flows. Definite-lived intangible assets are stated at cost, net of amortization, and generally amortized over their remaining estimated useful lives, ranging from seven to twelve years, based on the straight-line amortization method. In the case of certain NDAs and product rights assets, an accelerated amortization method is used to better match the anticipated economic benefits expected to be provided. Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that these asset might be impaired.

During the quarter ended September 30, 2024, the Company acquired Alimera, and as a result, acquired two intangible assets for YUTIQ and ILUVIEN, in the amount of $170.0 million and $230.0 million, respectively, which will be amortized over 12 years.

Amortization expense for definite-lived intangibles was $13.9 million and $13.3 million for the three months ended September 30, 2024 and 2023, respectively. Amortization expense for definite-lived intangibles was $39.8 million and $39.0 million for the nine months ended September 30, 2024 and 2023, respectively. No impairment losses were recognized in the three and nine months ended September 30, 2024 and 2023.

Indefinite-lived intangible assets other than goodwill include primarily In-Process Research & Development (“IPR&D”) projects. IPR&D intangible assets represent the fair value of technology acquired in a business combination or asset acquisition for which the technology projects are incomplete but have substance or alternative future use. When an IPR&D project is completed (generally upon receipt of regulatory approval), then the IPR&D will be accounted for as a definite-lived intangible asset.

Indefinite-lived intangible assets are not amortized, and the Company tests for impairment of indefinite-lived intangible assets when events or circumstances indicate that the carrying value of the assets may not be recoverable, and the Company performs an asset impairment analysis annually, as of October 31. No impairment losses were recognized in the three and nine months ended September 30, 2024 and 2023, respectively.

Expected future amortization expense for definite-lived intangible assets is as follows:


(in thousands)
2024 (remainder of the year)	$	20,647
2025	81,016
2026	67,531
2027	58,564
2028	51,783
2029 and thereafter	270,484
Total	$	550,025

BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Details) $ in Thousands, $ in Millions	Sep. 30, 2024 USD ($) facility	Mar. 28, 2024 USD ($)	Feb. 16, 2024 USD ($)	Feb. 16, 2024 CAD ($)	Feb. 15, 2024 USD ($)	Feb. 15, 2024 CAD ($)	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
Number of pharmaceutical manufacturing facilities \| facility	3
Assets held for sale \| $	$ 0						$ 8,020
Disposal Group, Held-for-Sale, Not Discontinued Operations \| Oakville, Ontario Former Manufacturing Facility
Debt Instrument [Line Items]
Consideration		$ 13,500	$ 14,200	$ 19.2	$ 14,200	$ 19.2

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

INVENTORIES - Schedule of inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 67,228	$ 62,237
Packaging materials	10,522	9,617
Work-in-progress	4,144	3,144
Finished goods	66,148	36,198
Inventories	$ 148,042	$ 111,196

2.25% CONVERTIBLE SENIOR NOTES

9 Months Ended

Sep. 30, 2024

Debt Disclosure [Abstract]

2.25% CONVERTIBLE SENIOR NOTES

TRUIST CREDIT FACILITY

In connection with the acquisition of Novitium on November 19, 2021, the Company, as borrower, entered into a credit agreement (the “Credit Agreement”) with Truist Bank and other lenders, which provided for credit facilities consisting of (i) a senior secured term loan facility in an aggregate principal amount of $300.0 million (the “Term Facility”) and (ii) a senior secured revolving credit facility in an aggregate commitment amount of $40.0 million, which provided for revolving credit loans, swingline loans and letters of credit (the “Revolving Facility,” and together with the Term Facility, the “Credit Facility”).

The Company incurred $14.0 million in deferred debt issuance costs associated with the Credit Facility. Costs allocated to the Term Facility were classified as a direct reduction to the current and non-current portion of the borrowings, depending on their nature. Costs allocated to the Revolving Facility were classified as other current and other non-current assets, depending on their nature. A commitment fee of 0.5% per annum was assessed on any unused portion of the Revolving Facility.

The carrying value of the current and non-current components of the Term Facility as of September 30, 2024 and December 31, 2023 are:


	Current
(in thousands)	September 30, 2024		December 31, 2023
Current borrowing on debt	$	—	$	3,000
Deferred financing costs	—		(2,150)
Current debt, net of deferred financing costs	$	—	$	850


	Non-Current
(in thousands)	September 30, 2024		December 31, 2023
Non-current borrowing on debt	$	—	$	291,000
Deferred financing costs	—		(6,181)
Non-current debt, net of deferred financing costs and current component	$	—	$	284,819

The following table sets forth the components of total interest expense related to the Term Facility, as recognized in the accompanying unaudited interim condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	2,883	$	7,864	$	16,644	$	22,834
Amortization of deferred financing costs	295		591		1,477		1,773
Capitalized interest	(138)		(142)		(401)		(440)
	$	3,040	$	8,313	$	17,720	$	24,167

Extinguishment of the Credit Facility

On August 13, 2024, the Company entered into an indenture with U.S. Bank Trust Company, National Association, as trustee, for the issuance of the 2.25% Convertible Senior Notes due 2029 (as described in Note 7 “2.25% Convertible Senior Notes” to the Notes to Condensed Consolidated Financial Statements). The proceeds of the Convertible Senior Notes and cash on-hand were used to repay the Credit Facility in its entirety, approximately $294.0 million, comprised of $292.5 million of unpaid principal, $1.2 million in accrued and unpaid interest, and $0.3 million of legal fees. In connection with the issuance of the Convertible Senior Notes, the Company recorded a loss on debt extinguishment in the unaudited interim consolidated statement of operations for the three and nine months ended September 30, 2024, amounting to approximately $7.5 million, comprised of the write-off unamortized deferred financing fees related to the Credit Facility as of August 13, 2024.

New Credit Agreement

On August 13, 2024, the Company, as lead borrower, and ANIP Acquisition Company, as initial subsidiary borrower (“ANIP”) entered into a credit agreement (the “New Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, and the financial institutions party thereto as lenders (together, the “Lenders”), which provides for aggregate principal commitments consisting of (i) a senior secured delayed-draw term loan facility in an aggregate principal amount of $325.0 million (the “Term Loan A” or “TLA”), and (ii) a senior secured revolving credit facility in an aggregate commitment amount of $75.0 million, which may be used for revolving credit loans, swingline loans and letters of credit (the “TLA Revolver” and together with the TLA, the “New Credit Facility”).

On September 16, 2024 (the “Closing Date”), ANIP drew the full $325.0 million of Term Loan A principal, with proceeds used to finance the acquisition of Alimera, including fees, costs and expenses incurred in connection with the acquisition. As of September 30, 2024, the TLA Revolver remains undrawn, and $75.0 million is available for borrowing, subject to the satisfaction of certain conditions. The TLA and the TLA Revolver mature on September 16, 2029. The New Credit Facility contains certain contingent acceleration clauses that could result in an earlier maturity date, none of which have been triggered as of September 30, 2024.

The cash interest rate and effective rate under the Term Loan A was approximately 7.95% and 8.37% per annum at September 30, 2024, respectively.

The Company incurred $5.0 million in deferred debt issuance costs associated with the TLA, which costs are classified as a direct reduction to the current and non-current portion of debt. The Company incurred $1.1 million in deferred debt issuance costs associated with the TLA Revolver, which costs are classified as other non-current assets. A commitment fee accrues on the unutilized commitments under the TLA Revolver and, from and after the date that is two months after the closing date of the New Credit Agreement, the TLA at a per annum rate equal between 0.25% and 0.40% depending on the Company’s first lien net leverage ratio.

The New Credit Facility is secured by a lien on substantially all of the Company’s and its principal domestic subsidiary’s assets and any future domestic subsidiary guarantors’ assets. The New Credit Facility is subject to customary financial and nonfinancial covenants.

The Company is required to make quarterly principal payments, beginning on December 31, 2024, in the amount of (i) 0.625% of the original principal amount of the Term Loan A on each quarterly payment date on or prior to the one year anniversary of the Closing Date, (ii) 1.25% of the original principal amount of the Term Loan A on each quarterly payment date following the one year anniversary of the Closing Date and 1.875% of the original principal amount of the Term Loan A on each quarterly payment date following the three year anniversary of the Closing Date and with the remaining unpaid principal amount due on the maturity date of the Term Loan A.

The carrying value of the current and non-current components of the New Credit Facility as of September 30, 2024 and December 31, 2023 are:


	Current
(in thousands)	September 30, 2024		December 31, 2023
Current borrowing on debt	$	8,125	$	—
Deferred financing costs	(973)		—
Current debt, net of deferred financing costs	$	7,152	$	—


	Non-Current
(in thousands)	September 30, 2024		December 31, 2023
Non-current borrowing on debt	$	316,875	$	—
Deferred financing costs	(3,957)		—
Non-current debt, net of deferred financing costs and current component	$	312,918	$	—

Of the $1.1 million of unamortized deferred debt issuance costs allocated to the New Credit Facility, $0.9 million is included in other non-current assets in the unaudited interim condensed consolidated balance sheets, and $0.2 million is included in prepaid expenses and other current assets in the unaudited interim condensed consolidated balance sheets.

The contractual maturity of the Term Loan A is as follows for the period ending:


(in thousands)	New Term Facility
2024 (remainder of the year)	$	2,031
2025	10,156
2026	18,281
2027	24,375
2028	24,375
2029	245,782
Total	$	325,000

The following table sets forth the components of total interest expense related to the Term Loan A during the three and nine months ended September 30, 2024 and 2023, as recognized in the accompanying unaudited interim condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	530	$	—	$	530	$	—
Amortization of deferred financing costs	49		—		49		—
	$	579	$	—	$	579	$	—

2.25% CONVERTIBLE SENIOR NOTES

Offering of Convertible Senior Notes

On August 7, 2024, the Company entered into a purchase agreement (the “Purchase Agreement”) with the initial purchasers (the “Initial Purchasers”) relating to the issuance of the $275.0 million aggregate principal amount of the Company's Convertible Senior Notes due 2029 (the “Notes”). Pursuant to the terms of the Purchase Agreement, the Company granted the Initial Purchasers an option to purchase up to an additional $41.25 million aggregate principal amount of Notes (the “Option”) for settlement at any time during the thirteen days beginning on, and including August 7, 2024, which Option was exercised in full on August 8, 2024.

On August 13, 2024 (the “Closing Date” or “Issue Date”), the Company completed an offering of $316.25 million aggregate principal amount of Notes. The Notes were issued pursuant to an indenture (the “Indenture”) dated as of August 13, 2024 between the Company and U.S. Bank Trust Company, National Association (“Trustee”). The Notes are due September 1, 2029, unless earlier repurchased, redeemed, or converted. The Notes will accrue interest at a rate of 2.25% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on March 1, 2025. After deducting the initial purchasers’ discounts and commissions of approximately $9.5 million, but before deducting the Company’s offering expenses, the net proceeds to the Company from the offering of the Notes was approximately $306.8 million. After payment of the cost of entering into the Capped Call Transactions (as defined below), the Company used the remainder of the net proceeds from the Notes offering, together with cash on hand, to repay the Company’s existing senior secured credit agreement, dated as of November 19, 2021, by and among the Company, certain of the Company’s subsidiaries, as guarantors, Truist Bank, as administrative agent, and other parties thereto, as amended, supplemented or otherwise modified from time to time (as amended, the “Credit Agreement”). Refer to Note 5 “Truist Credit Facility” to the Notes to Condensed Consolidated Financial Statements for the details of the extinguishment of the Credit Agreement.

The Notes are the Company’s senior, unsecured obligations and are (i) equal in right of payment with the Company’s existing and future senior, unsecured indebtedness; (ii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated to the Notes; (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries.

Conversion Options

Prior to the close of business on the business day immediately preceding June 1, 2029, holders of the Notes will have the right to convert their Notes only upon the occurrence of certain events as set forth in the Indenture. All or any portion of the Notes may be converted prior to June 1, 2029 at the holders’ option upon the occurrence of any of the following: (i) during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on September 30, 2024, if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price of the Notes for each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (ii) during the five consecutive business days immediately after any ten consecutive trading day period (such ten consecutive trading day period, the “measurement period”) in which the trading price per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company’s common stock on such trading day and the conversion rate of the Notes on such trading day; (iii) upon the occurrence of certain corporate events or distributions on the Company's common stock, as described in the Indenture; or (iv) if the Company calls such Notes for redemption.

On or after June 1, 2029 until the close of business on the second scheduled trading day immediately before the maturity date of the Notes, holders may convert all or any portion of their Notes at any time at their election. The initial conversion rate for the Notes is 13.4929 shares of the Company’s common stock per $1,000 principal amount of Notes, which represents an initial conversion price of approximately $74.11 per share of the Company’s common stock. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased for holders that convert their Notes in connection with such Make-Whole Fundamental Change, as described in the Indenture.

Upon conversion of the Notes, the Company will pay cash up to the aggregate principal amount of the Notes to be converted and pay or deliver, as the case may be, cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company’s election, in respect of the remainder, if any, of the Company's conversion obligation.

The Notes will be redeemable, in whole or in part (subject to certain limitations described below), at the Company’s option at any time, and from time to time, on or after September 1, 2027 and on or before the 61st scheduled trading day immediately before the maturity date, but only if (i) the notes are “Freely Tradable” (as defined in the Indenture) as of the date the Company sends the related redemption notice and all accrued and unpaid additional interest, if any, has been paid in full as of the first interest payment date occurring on or before the date the Company sends the related redemption notice; and (ii) the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price on (1) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends such redemption notice; and (2) the trading day immediately before the date the Company sends such redemption notice. However, the Company may not redeem less than all of the outstanding Notes unless at least $75.0 million aggregate principal amount of Notes are outstanding and not called for redemption as of the time the Company sends the related redemption notice. The redemption price will be a cash amount equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted with a conversion date that is on or after the date the Company sends the related redemption notice and on or before the second business day immediately before the related redemption date.

If certain corporate events that constitute a “Fundamental Change” (as defined in the Indenture) occur, then, subject to a limited exception for certain cash mergers, holders of the Notes may require the Company to repurchase their Notes at a cash repurchase price equal to the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. The definition of Fundamental Change includes certain business combination transactions involving the Company and certain de-listing events with respect to the Company’s common stock.

Events of Default

The Notes include customary provisions relating to the occurrence of “Events of Default” (as defined in the Indenture), including breaches of covenants, breaches of warranty, change of control, nonpayment, bankruptcy, assignment, foreclosure, cessation of business, and defaults under ancillary documents. Certain of the Events of Default are subject to notice and cure periods. As of September 30, 2024, the Company was in compliance with all covenants associated with the Notes.

Debt issuance costs related to the Notes totaled $11.2 million at inception and were comprised of discounts and commissions payable to the initial purchasers and third-party offering costs and will be amortized to interest expense using the effective interest method over the contractual term. As of September 30, 2024, the unamortized debt discount and debt issuance cost of the Notes was approximately $11.0 million on the unaudited interim condensed consolidated balance sheets. The effective interest rate during the quarter ended September 30, 2024 was 3.01%.

During the quarter ended September 30, 2024, the Notes did not meet any of the circumstances that would allow for a conversion. The Notes were therefore not convertible as of September 30, 2024, and were classified as long-term debt on the Company’s unaudited interim condensed consolidated balance sheet as of September 30, 2024.

As of September 30, 2024, the total estimated fair value (which represents a Level 2 valuation) of the Notes is approximately $334.8 million.

The following table sets forth the components of total interest expense related to the Notes during the three and nine months ended September 30, 2024 and 2023, as recognized in the accompanying unaudited interim condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	969	$	—	$	969	$	—
Amortization of finance fees	281		—		281		—
	$	1,250	$	—	$	1,250	$	—

Capped Call Transactions

In connection with the offering of Notes, on August 7, 2024 and August 8, 2024, the Company entered into capped call transactions with certain financial institutions (“Capped Calls”). The Capped Calls each have an initial cap price of $114.02, which represents a premium of 100% over the last reported sale price of the Company’s common stock on August 7, 2024. The Company used approximately $40.6 million of the net proceeds from the offering of the Notes to pay premiums on the Capped Calls.

The Capped Calls are expected to generally to reduce potential dilution to the Company’s common stock upon any conversion of the Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes. The Capped Calls cover, subject to anti-dilution adjustments, approximately 4.3 million shares of the Company's common stock.

The Capped Calls will expire upon the maturity of the Notes. The Capped Calls are separate transactions entered into by the Company with the financial institution counterparties thereto, the Capped Calls are not part of the terms of the Notes and the Capped Calls do not change the holders’ rights under the Notes. The Capped Calls do not meet the criteria for separate accounting as a derivative as they meet the criteria for equity classification, and the capped call transaction premiums are recorded as a reduction to Additional Paid-In Capital within Shareholders’ Equity, net of deferred income taxes.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

TRUIST CREDIT FACILITY - Facility components (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Current debt, net of deferred financing costs	$ 7,152	$ 850
Non-current debt, net of deferred financing costs and current component	312,918	284,819
Term Loan and DDTL
Debt Instrument [Line Items]
Current borrowing on debt	0	3,000
Deferred financing costs	0	(2,150)
Current debt, net of deferred financing costs	0	850
Non-current borrowing on debt	0	291,000
Deferred financing costs	0	(6,181)
Non-current debt, net of deferred financing costs and current component	$ 0	$ 284,819

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

BUSINESS COMBINATION (Tables)

9 Months Ended

Sep. 30, 2024

Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]

Schedule of business acquisitions, by acquisition

Purchase consideration consisted of the following:


(In thousands, except share price and exchange ratio)	Purchase Consideration
Alimera common shares outstanding	53,971
Alimera warrants outstanding after exercise	989
Alimera common shares and warrants outstanding	54,960
Cash consideration per share	$	5.50
Cash consideration for Alimera Common Stock	$	302,280

Repayment of Alimera Debt	78,540
Payment of Alimera transaction costs	20,172
Cash settlement for pre-acquisition equity awards	9,535
Fair value of CVRs	8,322
Total Merger Consideration	$	418,849

Schedule of recognized identified assets acquired and liabilities assumed

The allocation of the fair value will be finalized when the valuation is completed, and the differences will be trued up for the final allocated amounts.


	Fair Value
Cash and cash equivalents	$	9,247
Accounts receivable	38,605
Prepaid expenses and other assets	2,618
Inventories	19,457
Property and equipment	3,086
Intangible assets	400,000
Deferred tax asset, net of deferred tax liabilities and valuation allowance	198
Derivative and other non-current assets	1,224
Total assets	$	474,435

Accounts payable	$	8,001
Accrued expenses and other	11,396
Returned goods reserve	3,095
Current accrued licensor payment	3,684
Accrued licensor payment, net of current	21,316
Deferred tax liability	37,932
Other non-current liabilities	2,364
Total liabilities	$	87,788

Total fair value of consideration transferred	$	418,849
Less: fair value of net acquired identifiable assets and liabilities	386,647
Goodwill	$	32,202

Schedule of finite-lived intangible assets acquired as part of business combination

The following table summarizes the estimated fair value of identifiable intangible assets acquired and their remaining amortization period (in years):


	Fair Value (in thousands)		Useful Life
ILUVIEN	$	230,000	12
YUTIQ	$	170,000	12

Schedule of business acquisition, pro forma consolidated financial information

The following unaudited pro forma financial information summarizes the results of operations for the periods indicated as if the Acquisition had been completed as of January 1, 2023.


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Net revenues	$	162,700	$	155,193	$	488,180	$	409,610
Net (loss) income	$	(18,749)	$	2,327	$	(17,754)	$	(44,164)

Insider Trading Arrangements	3 Months Ended	9 Months Ended
Insider Trading Arrangements	Sep. 30, 2024 shares	Sep. 30, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		(c) Our directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or may represent a non-Rule 10b5-1 trading arrangement under the Exchange Act. On August 23, 2024 Krista Davis, Senior Vice President and Chief Human Resources Officer of the Company, adopted a Rule 10b5-1 trading plan for the period commencing three months from such date and ending on November 3, 2025 for sale of up to 5,866 shares of common stock of the Company. On September 17, 2024, Meredith Cook, Senior Vice President, General Counsel and Corporate Secretary of the Company, adopted a Rule 10b5-1 trading plan for the period commencing three months from such date and ending on December 31, 2025 for sale of up to 4,800 shares of common stock of the Company. On August 14, 2024, Muthusamy Shanmugam, Head of Research and Development and COO of New Jersey Operations of the Company, terminated his existing Rule 10b5-1 trading plan. Subsequently, on September 19, 2024, Muthusamy Shanmugam, adopted a Rule 10b5-1 trading plan for the period commencing three months from such date and ending on May 30, 2025 for sale of up to 200,000 shares of common stock of the Company.
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Krista Davis [Member]
Trading Arrangements, by Individual
Name	Krista Davis
Title	Senior Vice President and Chief Human Resources Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	August 23, 2024
Expiration Date	November 3, 2025
Arrangement Duration	437 days
Aggregate Available	5,866	5,866
Meredith Cook [Member]
Trading Arrangements, by Individual
Name	Meredith Cook
Title	Senior Vice President, General Counsel and Corporate Secretary
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	September 17, 2024
Expiration Date	December 31, 2025
Arrangement Duration	470 days
Aggregate Available	4,800	4,800
Muthusamy Shanmugam [Member]
Trading Arrangements, by Individual
Name	Muthusamy Shanmugam
Title	Head of Research and Development and COO
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	September 19, 2024
Rule 10b5-1 Arrangement Terminated	true
Termination Date	August 14, 2024
Expiration Date	May 30, 2025
Arrangement Duration	253 days
Aggregate Available	200,000	200,000

REVENUE RECOGNITION AND RELATED ALLOWANCES

9 Months Ended

Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

REVENUE RECOGNITION AND RELATED ALLOWANCES

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized using the following steps:

•Identification of the contract, or contracts, with a customer;

•Identification of the performance obligations in the contract;

•Determination of the transaction price, including the identification and estimation of variable consideration;

•Allocation of the transaction price to the performance obligations in the contract; and

•Recognition of revenue when we satisfy a performance obligation.

Revenues are primarily derived from sales of rare disease, generic, and established brand pharmaceutical products, royalties, and other pharmaceutical services. Revenue is recognized when obligations under the terms of contracts with customers are satisfied, which generally occurs when control of the products sold are transferred to the customer. Variable consideration is estimated after the consideration of applicable information that is reasonably available. The Company generally does not have incremental costs to obtain contracts that would otherwise not have been incurred. The Company does not adjust revenue for the promised amount of consideration for the effects of a significant financing component because our customers generally pay us within 100 days.

All revenue recognized in the accompanying unaudited interim condensed consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue:


	Three Months Ended September 30,				Nine Months Ended September 30,
Products and Services (in thousands)	2024		2023		2024		2023
Rare Disease
Sales of Cortrophin Gel	$	52,555	$	29,734	$	138,685	$	70,368
Sales of ILUVIEN and YUTIQ	3,871		—		3,871		—
Total sales of rare disease pharmaceutical products	$	56,426	$	29,734	$	142,556	$	70,368
Generics, Established Brands, and Other
Sales of generic pharmaceutical products	$	78,223	$	70,593	$	222,404	$	197,623
Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services	13,683		31,502		58,842		87,171
Total sales of generic and established brand pharmaceutical products, royalties, and other pharmaceuticals services	91,906		102,095		281,246		284,794
Total net revenues	$	148,332	$	131,829	$	423,802	$	355,162


	Three Months Ended September 30,				Nine Months Ended September 30,
Timing of Revenue Recognition (in thousands)	2024		2023		2024		2023
Performance obligations transferred at a point in time	$	148,332	$	131,829	$	423,802	$	354,787
Performance obligations transferred over time	—		—		—		375
Total	$	148,332	$	131,829	$	423,802	$	355,162

In the three and nine months ended September 30, 2024 and 2023, the Company did not incur, and therefore did not defer, any material incremental costs to obtain or fulfill contracts. The Company recognized a decrease of $3.3 million to net revenue from performance obligations satisfied in prior periods during the nine months ended September 30, 2024, consisting primarily of revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales. The Company recognized an increase of $8.5 million to net revenue from performance obligations satisfied in prior periods during the nine months ended September 30, 2023, consisting primarily of revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales. Additionally, as of September 30, 2024, and December 31, 2023, there was deferred revenue of approximately $5.0 million and $0.0 million, respectively, recorded on the condensed consolidated balance sheets in accrued expenses and other.

As of September 30, 2024, the aggregate amount of the transaction price allocated to the remaining performance obligations for all open contract manufacturing customer contracts was $3.8 million, which consists of firm orders for contract manufactured products. The Company recognizes revenue for these performance obligations as they are satisfied, which is anticipated within six months.

Variable consideration

Sales of pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative and other rebates, and cash discounts. Estimates for these elements of variable consideration require significant judgment.

The following table summarizes activity in the condensed consolidated balance sheets for accruals and allowances for the nine months ended September 30, 2024 and 2023, respectively:


	Accruals for Chargebacks, Returns, and Other Allowances
(in thousands)	Chargebacks		Government Rebates		Returns		Administrative Fees and Other Rebates		Prompt Payment Discounts
Balance at December 31, 2022	$	148,562	$	10,872	$	33,399	$	9,442	$	6,488
Accruals/Adjustments	437,671		16,998		13,048		40,815		17,024
Credits Taken Against Reserve	(501,841)		(16,947)		(15,009)		(39,316)		(18,366)
Balance at September 30, 2023 (1)	$	84,392	$	10,923	$	31,438	$	10,941	$	5,146

Balance at December 31, 2023	$	84,208	$	12,168	$	29,678	$	11,412	$	4,865
Impact of Alimera acquisition	95		—		3,095		671		—
Accruals/Adjustments	403,201		19,757		28,737		44,622		17,159
Credits Taken Against Reserve	(410,508)		(21,232)		(24,442)		(43,486)		(17,218)
Balance at September 30, 2024 (1)	$	76,996	$	10,693	$	37,068	$	13,219	$	4,806

______________________________________________

(1)Chargebacks and Prompt Payment Discounts are included as an offset to accounts receivable in the unaudited interim condensed consolidated balance sheets. Administrative Fees and Other Rebates are included as an offset to accounts receivable or as accrued expenses and other in the unaudited interim condensed consolidated balance sheets. Returns are included in returned goods reserve in the unaudited interim condensed consolidated balance sheets. Government Rebates are included in accrued government rebates in the unaudited interim condensed consolidated balance sheets.

Credit Concentration

ANI’s customers are primarily wholesale distributors, chain drug stores, group purchasing organizations, pharmaceutical companies, hospitals, and healthcare providers.

During the three and nine months ended September 30, 2024, there were four customers that accounted for 10% or more of net revenues. During the three and nine months ended September 30, 2023, there were four customers that accounted for 10% or more of net revenues. As of September 30, 2024, accounts receivable from five customers totaled 71% of Accounts receivable, net.

The four customers represent the total percentage of net revenues as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Customer 1	20	%	35	%	26	%	33	%
Customer 2	10	%	12	%	12	%	13	%
Customer 3	14	%	12	%	12	%	13	%
Customer 4	17	%	13	%	15	%	10	%

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

FAIR VALUE DISCLOSURES - Level 3 (Details) $ in Thousands	3 Months Ended		9 Months Ended
FAIR VALUE DISCLOSURES - Level 3 (Details) $ in Thousands	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Changes in contingent consideration
Beginning balance	$ 11,933	$ 37,054	$ 23,984	$ 35,058
Payment of Gross-Profit earn-out	0	0	(12,500)	0
CVR Agreement	$ 825	$ (2,555)	$ 1,274	$ (559)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Contingent consideration fair value adjustment	Contingent consideration fair value adjustment	Contingent consideration fair value adjustment	Contingent consideration fair value adjustment
Ending balance	$ 12,758	$ 34,499	$ 12,758	$ 34,499
Discount rate \| Probability-weighted discounted cash flow \| Profit-based milestone payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable inputs	0.12		0.12

REVENUE RECOGNITION AND RELATED ALLOWANCES - Allowances (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Accruals for Chargebacks, Returns, and Other Allowances
Beginning balance	$ 97,262
Ending balance	91,008
Chargebacks
Accruals for Chargebacks, Returns, and Other Allowances
Beginning balance	84,208	$ 148,562
Accruals/Adjustments	403,201	437,671
Impact of Alimera acquisition	95
Credits Taken Against Reserve	(410,508)	(501,841)
Ending balance	76,996	84,392
Government Rebates
Accruals for Chargebacks, Returns, and Other Allowances
Beginning balance	12,168	10,872
Accruals/Adjustments	19,757	16,998
Impact of Alimera acquisition	0
Credits Taken Against Reserve	(21,232)	(16,947)
Ending balance	10,693	10,923
Returns
Accruals for Chargebacks, Returns, and Other Allowances
Beginning balance	29,678	33,399
Accruals/Adjustments	28,737	13,048
Impact of Alimera acquisition	3,095
Credits Taken Against Reserve	(24,442)	(15,009)
Ending balance	37,068	31,438
Administrative Fees and Other Rebates
Accruals for Chargebacks, Returns, and Other Allowances
Beginning balance	11,412	9,442
Accruals/Adjustments	44,622	40,815
Impact of Alimera acquisition	671
Credits Taken Against Reserve	(43,486)	(39,316)
Ending balance	13,219	10,941
Prompt Payment Discounts
Accruals for Chargebacks, Returns, and Other Allowances
Beginning balance	4,865	6,488
Accruals/Adjustments	17,159	17,024
Impact of Alimera acquisition	0
Credits Taken Against Reserve	(17,218)	(18,366)
Ending balance	$ 4,806	$ 5,146

2.25% CONVERTIBLE SENIOR NOTES - Capped Call Transactions (Details) - Call Option $ / shares in Units, $ in Millions	Aug. 13, 2024 USD ($) $ / shares shares
Debt Instrument [Line Items]
Derivative capped call price per share (in dollars per share) \| $ / shares	$ 114.02
Derivative, percentage premium	100.00%
Payments for capped call transactions \| $	$ 40.6
Number of shares covered by derivative instrument upon conversion (in shares) \| shares	4,300,000

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

INVENTORIES (Tables)

9 Months Ended

Sep. 30, 2024

Inventory Disclosure [Abstract]

Schedule of inventories

Inventories consist of the following as of:


(in thousands)	September 30, 2024		December 31, 2023
Raw materials	$	67,228	$	62,237
Packaging materials	10,522		9,617
Work-in-progress	4,144		3,144
Finished goods	66,148		36,198
Inventories	$	148,042	$	111,196

REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Total net revenues	$ 148,332	$ 131,829	$ 423,802	$ 355,162
Total sales of rare disease pharmaceutical products
Disaggregation of Revenue [Line Items]
Total net revenues	56,426	29,734	142,556	70,368
Sales of Cortrophin Gel
Disaggregation of Revenue [Line Items]
Total net revenues	52,555	29,734	138,685	70,368
Sales of ILUVIEN and YUTIQ
Disaggregation of Revenue [Line Items]
Total net revenues	3,871	0	3,871	0
Total sales of generic and established brand pharmaceutical products, royalties, and other pharmaceuticals services
Disaggregation of Revenue [Line Items]
Total net revenues	91,906	102,095	281,246	284,794
Sales of generic pharmaceutical products
Disaggregation of Revenue [Line Items]
Total net revenues	78,223	70,593	222,404	197,623
Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services
Disaggregation of Revenue [Line Items]
Total net revenues	$ 13,683	$ 31,502	$ 58,842	$ 87,171

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company’s financial position, results of operations, comprehensive (loss) income, and cash flows. The consolidated balance sheet at December 31, 2023 has been derived from audited financial statements as of that date. The unaudited interim condensed consolidated statements of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the U.S. Securities and Exchange Commission (the “SEC”). Therefore, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto previously distributed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”), as filed with the SEC.
Principles of Consolidation	Principles of Consolidation The unaudited interim condensed consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.
Foreign Currency	Foreign Currency The Company currently has subsidiaries located in India, Ireland, Germany, and the United Kingdom. The India-based subsidiary generally conducts its transactions in Indian upees, which is also its functional currency. The Ireland and Germany locations generally conduct their transactions in Euros, which is also their functional currency. The United Kingdom subsidiary conducts its transactions in Euros and British Pounds, and their functional currency is Euros. The Company has ceased operations at its subsidiary in Oakville, Ontario, Canada as of March 31, 2023. The Canada-based subsidiary conducted its transactions in U.S. dollars and Canadian dollars, but its functional currency was the U.S. dollar. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net (loss) income. The gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the three and nine months ended September 30, 2024 and 2023. Unless otherwise noted, all references to “$” or “dollar” refer to the U.S. dollar. The Company’s asset and liability accounts are translated using the current exchange rate as of the balance sheet date, except for shareholders’ equity accounts, which are translated using historical rates. Net revenues and expense accounts are translated using an average exchange rate over the period ended on the balance sheet date. Adjustments resulting from the translation of the financial statements of the Company’s foreign subsidiaries into U.S. dollars are accumulated as a separate component of shareholders’ equity within accumulated other comprehensive (loss) income, net of tax.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the condensed consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, income tax provision or benefit, deferred taxes and valuation allowance, stock-based compensation, revenue recognition, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration and contingent value rights in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.
Business Combinations And Goodwill	Business Combination and Goodwill The Company accounted for its acquisition of Alimera using the acquisition method of accounting prescribed by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 805, Business Combinations, whereby the results of operations, including the revenues and earnings of Alimera, are included in the financial statements from the date of acquisition. Assets acquired and liabilities assumed as of the date of acquisition are recognized at their fair values based on widely accepted valuation techniques in accordance with ASC 820, Fair Value Measurements. Goodwill is recognized for the excess of the consideration transferred over the net fair values of assets acquired and liabilities assumed. Management’s assessment of qualitative factors affecting goodwill for each acquisition includes estimates of market share at the date of purchase, ability to grow in the market, synergy with existing Company operations and the payor profile in the markets. The fair value assigned to the intangible assets was determined using the income approach, specifically the multi-period excess earnings methodology. The process for estimating fair values requires the use of significant estimates, assumptions and judgments, including determining the timing and estimates of future cash flows and developing appropriate discount rates. The estimates of fair value are based upon assumptions believed to be reasonable using the best information available. These assumptions are inherently uncertain and unpredictable and, as a result, actual results may differ materially from estimates. ASC 805, Business Combinations, establishes a measurement period to provide the Company with a reasonable amount of time to obtain the information necessary to identify and measure various items in a business combination and cannot extend beyond one year from the acquisition date. Measurement period adjustments are recognized in the reporting period in which the adjustments are determined and calculated as if the accounting had been completed as of acquisition date. The Company expects to complete the final fair value determination of the assets acquired and liabilities assumed as soon as practicable within the measurement period, but not to exceed one year from the acquisition date
Investment in Equity Securities	Investment in Equity Securities The Company accounts for its investment in equity securities with a readily determinable fair value in accordance with the guidance in ASC 321, Investments – Equity Securities. The Company presents unrealized gains and losses related to the equity securities, within Unrealized gain on investment in equity securities in its unaudited condensed consolidated statements of operations. Fair values are obtained from quoted prices on the NASDAQ Stock Market, Inc. (“NASDAQ”).
Assets Held-for-Sale	Assets Held-for-Sale The Company classifies assets held-for-sale if all held-for-sale criteria is met pursuant to ASC 360-10, Property, Plant and Equipment. Criteria include management commitment to sell the disposal group in its present condition and the sale being deemed probable of being completed within one year. Assets classified as held-for-sale are not depreciated and are measured at the lower of their carrying amount or fair value less cost to sell. The Company assesses the fair value of a disposal group, less any costs to sell, each reporting period it remains classified as held-for-sale and reports any subsequent changes as an adjustment to the carrying value of the disposal group, as long as the new carrying value does not exceed the initial carrying value of the disposal group. The Company determined that the Oakville, Ontario, Canada property met the held-for-sale criteria. As of December 31, 2023, approximately $8.0 million of assets held for sale were recorded on the consolidated balance sheets. The Oakville, Ontario property was sold on March 28, 2024 (see Note 4 “Restructuring Canada Operations” to the Notes to Condensed Consolidated Financial Statements).
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures related to significant segment expenses. The guidance in this ASU is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. While this ASU will increase and enhance disclosures, it will not have a material impact on the Company's consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes guidance to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. These amendments are effective for all public entities for fiscal periods beginning after December 15, 2024, with early adoption permitted. These amendments apply on a prospective basis, but entities have an option to apply it retrospectively for all periods presented. Recent Securities and Exchange Commission Final Rules Issued but Not Yet Effective On March 6, 2024, the SEC adopted new rules that will require registrants to disclose certain climate-related information in their annual reports. The final rule requires disclosure of, among other things: material climate-related risks and their material impacts; activities to mitigate or adapt to such risks; information about a registrant’s board of directors’ oversight of climate-related risks and management’s role in managing material climate-related risks; and information on any climate-related targets or goals that are material to the registrant’s business, results of operations, or financial condition. In addition, certain disclosures related to severe weather events and other natural conditions will be required in a registrant’s audited financial statements. The required information about climate-related risks will also include disclosure of a registrant’s greenhouse gas emissions. The Company will be subject to the applicable requirements of the final rule in our annual reports for fiscal years beginning on January 1, 2025. In April 2024, the SEC voluntarily stayed the rules pending judicial review. The Company is currently evaluating the potential impact of these rules on its consolidated financial statements and related disclosures.

- Definition

Disclosure of accounting policy for investment in financial asset.

+ References + Details

TRUIST CREDIT FACILITY

9 Months Ended

Sep. 30, 2024

Debt Disclosure [Abstract]

TRUIST CREDIT FACILITY

The carrying value of the current and non-current components of the Term Facility as of September 30, 2024 and December 31, 2023 are:


	Current
(in thousands)	September 30, 2024		December 31, 2023
Current borrowing on debt	$	—	$	3,000
Deferred financing costs	—		(2,150)
Current debt, net of deferred financing costs	$	—	$	850


	Non-Current
(in thousands)	September 30, 2024		December 31, 2023
Non-current borrowing on debt	$	—	$	291,000
Deferred financing costs	—		(6,181)
Non-current debt, net of deferred financing costs and current component	$	—	$	284,819


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	2,883	$	7,864	$	16,644	$	22,834
Amortization of deferred financing costs	295		591		1,477		1,773
Capitalized interest	(138)		(142)		(401)		(440)
	$	3,040	$	8,313	$	17,720	$	24,167

Extinguishment of the Credit Facility

New Credit Agreement

The cash interest rate and effective rate under the Term Loan A was approximately 7.95% and 8.37% per annum at September 30, 2024, respectively.

The carrying value of the current and non-current components of the New Credit Facility as of September 30, 2024 and December 31, 2023 are:


	Current
(in thousands)	September 30, 2024		December 31, 2023
Current borrowing on debt	$	8,125	$	—
Deferred financing costs	(973)		—
Current debt, net of deferred financing costs	$	7,152	$	—


	Non-Current
(in thousands)	September 30, 2024		December 31, 2023
Non-current borrowing on debt	$	316,875	$	—
Deferred financing costs	(3,957)		—
Non-current debt, net of deferred financing costs and current component	$	312,918	$	—

The contractual maturity of the Term Loan A is as follows for the period ending:


(in thousands)	New Term Facility
2024 (remainder of the year)	$	2,031
2025	10,156
2026	18,281
2027	24,375
2028	24,375
2029	245,782
Total	$	325,000


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	530	$	—	$	530	$	—
Amortization of deferred financing costs	49		—		49		—
	$	579	$	—	$	579	$	—

2.25% CONVERTIBLE SENIOR NOTES

Offering of Convertible Senior Notes

Conversion Options

Events of Default

As of September 30, 2024, the total estimated fair value (which represents a Level 2 valuation) of the Notes is approximately $334.8 million.


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	969	$	—	$	969	$	—
Amortization of finance fees	281		—		281		—
	$	1,250	$	—	$	1,250	$	—

Capped Call Transactions

- Definition

+ References

+ Details

TRUIST CREDIT FACILITY (Tables)

9 Months Ended

Sep. 30, 2024

Debt Disclosure [Abstract]

Schedule of carrying value of the current and non-current components of the term loan

The carrying value of the current and non-current components of the Term Facility as of September 30, 2024 and December 31, 2023 are:


	Current
(in thousands)	September 30, 2024		December 31, 2023
Current borrowing on debt	$	—	$	3,000
Deferred financing costs	—		(2,150)
Current debt, net of deferred financing costs	$	—	$	850


	Non-Current
(in thousands)	September 30, 2024		December 31, 2023
Non-current borrowing on debt	$	—	$	291,000
Deferred financing costs	—		(6,181)
Non-current debt, net of deferred financing costs and current component	$	—	$	284,819

The carrying value of the current and non-current components of the New Credit Facility as of September 30, 2024 and December 31, 2023 are:


	Current
(in thousands)	September 30, 2024		December 31, 2023
Current borrowing on debt	$	8,125	$	—
Deferred financing costs	(973)		—
Current debt, net of deferred financing costs	$	7,152	$	—


	Non-Current
(in thousands)	September 30, 2024		December 31, 2023
Non-current borrowing on debt	$	316,875	$	—
Deferred financing costs	(3,957)		—
Non-current debt, net of deferred financing costs and current component	$	312,918	$	—

Schedule of components of total interest expense related to the notes and term loan


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	2,883	$	7,864	$	16,644	$	22,834
Amortization of deferred financing costs	295		591		1,477		1,773
Capitalized interest	(138)		(142)		(401)		(440)
	$	3,040	$	8,313	$	17,720	$	24,167

Extinguishment of the Credit Facility


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	530	$	—	$	530	$	—
Amortization of deferred financing costs	49		—		49		—
	$	579	$	—	$	579	$	—


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	969	$	—	$	969	$	—
Amortization of finance fees	281		—		281		—
	$	1,250	$	—	$	1,250	$	—

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

+ Details

BUSINESS COMBINATION - Recognized identified assets acquired and liabilities assumed (Details) - USD ($) $ in Thousands	Sep. 16, 2024	Sep. 30, 2024	Dec. 31, 2023
Business Acquisition [Line Items]
Goodwill		$ 60,426	$ 28,221
Alimera Sciences, Inc
Business Acquisition [Line Items]
Cash and cash equivalents	$ 9,247
Accounts receivable	38,605
Prepaid expenses and other assets	2,618
Inventories	19,457
Property and equipment	3,086
Intangible assets	400,000
Deferred tax asset, net of deferred tax liabilities and valuation allowance	198
Derivative and other non-current assets	1,224
Total assets	474,435
Accounts payable	8,001
Accrued expenses and other	11,396
Returned goods reserve	3,095
Current accrued licensor payment	3,684
Accrued licensor payment, net of current	21,316
Deferred tax liability	37,932
Other non-current liabilities	2,364
Total liabilities	87,788
Total fair value of consideration transferred	418,849
Less: fair value of net acquired identifiable assets and liabilities	386,647
Goodwill	$ 32,202

2.25% CONVERTIBLE SENIOR NOTES - Narrative (Details) - Convertible Senior Notes due 2029 $ / shares in Units, $ in Thousands			9 Months Ended
	Aug. 13, 2024 USD ($) tradingDay $ / shares	Aug. 07, 2024 USD ($)	Sep. 30, 2024 USD ($) Rate
Convertible Debt
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	2.25%
Aggregate principal amount	$ 316,250	$ 275,000
Debt instrument accordion feature increase limit		$ 41,250
Debt instrument accordion feature settlement period		13 days
Payment of convertible debt discounts and commissions	9,500
Proceeds from issuance of debt	$ 306,800
Senior Notes
Debt Instrument [Line Items]
Debt instrument, convertible, threshold percentage of stock price trigger	130.00%
Debt instrument, convertible, threshold trading days \| tradingDay	20
Debt instrument, convertible, threshold consecutive trading days \| tradingDay	30
Debt instrument, convertible, conversion ratio \| Rate			1.34929%
Debt instrument, convertible, conversion price (in dollars per share) \| $ / shares	$ 74.11
Debt instrument convertible minimum aggregate principal outstanding	$ 75,000
Debt issuance costs, gross	$ 11,200
Debt instrument, unamortized discount (premium) and debt issuance costs, net			$ 11,000
Debt effective interest rate (as a percent)			3.01%
Senior Notes \| Level 2
Debt Instrument [Line Items]
Debt instrument, fair value disclosure			$ 334,800
Senior Notes \| Market Price Condition
Debt Instrument [Line Items]
Debt instrument, convertible, threshold percentage of stock price trigger	130.00%
Debt instrument, convertible, threshold trading days \| tradingDay	20
Debt instrument, convertible, threshold consecutive trading days \| tradingDay	30
Senior Notes \| Trading Price Condition
Debt Instrument [Line Items]
Debt instrument, convertible, threshold percentage of stock price trigger	98.00%
Debt instrument, convertible, threshold trading days \| tradingDay	5
Debt instrument, convertible, threshold consecutive trading days \| tradingDay	10

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Operating Leases In April 2023, the Company entered into an agreement to lease additional warehouse space in East Windsor, New Jersey. The lease has a term of five years, and is classified as an operating lease. Additionally, during October 2023, the Company entered into an amendment for the Middleton, Wisconsin location which expanded the Company’s square footage and also extended the termination date to December 2028. In connection with the acquisition of Alimera, the Company acquired operating leases for office space in Alpharetta, Georgia, and has a remaining term of approximately five years, and a lease for office space in the United Kingdom, which has a remaining term of less than one year. Rent expense is recognized on a straight-line basis over the lease term. Operating lease ROU assets are included in other non-current assets and operating lease liabilities are included in accrued expenses and other and other non-current liabilities in the consolidated balance sheets. Finance Leases In connection with the acquisition of Alimera, the Company acquired finance leases primarily consisting of automobiles. The property and equipment is capitalized at the lesser of fair market value or the present value of the minimum lease payments at the inception of the leases using the Company’s incremental borrowing rate. The Company’s finance lease agreements do not contain any material residual value guarantees or material restrictive covenants. Finance lease ROU assets are included in other non-current assets, specifically in Property and equipment, net, and finance lease liabilities are included in accrued expenses and other and other non-current liabilities in the consolidated balance sheets. Government Regulation The Company’s products and facilities are subject to regulation by a number of federal and state governmental agencies, such as the Drug Enforcement Administration (“DEA”), the Food and Drug Administration (“FDA”), the Centers for Medicare and Medicaid Services (“CMS”), the Central Drugs Standard Control Organization (“CDSCO”), The Narcotics Control Bureau (“NCB”), and India’s Ministry of Health and Family Welfare (“MoHFW”). The FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of ANI’s products. The DEA and NCB maintain oversight over products that are considered controlled substances. Unapproved Products Four products, Esterified Estrogens and Methyltestosterone (“EEMT”), Opium Tincture, Thyroid Tablets, and Hyoscyamine are sold without approved NDAs or ANDAs. If the FDA took enforcement action against the Company, the Company may be required to seek FDA approval for the group of products or withdraw them from the market. During the three and nine months ended September 30, 2024, net revenues from commercial sales of these products totaled $5.5 million and $16.4 million, respectively. During the three and nine months ended September 30, 2023, net revenues from EEMT and Opium Tincture totaled $9.2 million and $16.4 million, respectively. On December 27, 2023, the Company acquired from Alvogen, Inc. the rights to Hyoscyamine for total cash consideration of $2.0 million, which product was launched commercially in February 2024. Contract manufacturing revenues for Hyoscyamine, for both the three and nine months ended September 30, 2024 were less than $0.1 million. Contract manufacturing revenues for Hyoscyamine, for three and nine months ended September 30, 2023 were less than $0.1 million and $1.1 million, respectively. Legal proceedings The Company is, and from time to time may become, involved in various disputes, governmental and/or regulatory inquiries, investigations, government reimbursement related actions and litigation. These matters are complex and subject to significant uncertainties. While we believe that we have valid claims and/or defenses in the litigation and other matters described below, litigation is inherently unpredictable, particularly where the damages sought are substantial or indeterminate or when the proceedings, investigations or inquiries are in the early stages, and the outcome of the proceedings could result in losses, including substantial damages, fines, civil or criminal penalties and injunctive or administrative remedies. We intend to vigorously prosecute and/or defend these matters, as appropriate; however, from time to time, we may settle or otherwise resolve these matters on terms and conditions that we believe are in our best interests. Resolution of any or all claims, investigations, and legal proceedings, individually or in the aggregate, could have a material adverse effect on our results of operations and/or cash flows in any given accounting period or on our overall financial condition. Some of these matters with which we are involved are described below and in our 2023 Form 10-K, and unless otherwise disclosed, we are unable to predict the outcome of the matter or to provide an estimate of the range of reasonably possible material losses. We record accruals for loss contingencies to the extent we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. From time to time, we are also involved in other pending proceedings for which, in our opinion based upon facts and circumstances known at the time, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to our results, and therefore remain undisclosed. If and when any reasonably possible losses associated with the resolution of such other pending proceedings, in our opinion, become material, we will disclose such matters. Furthermore, like many pharmaceutical manufacturers, we are periodically exposed to product liability claims. The prevalence of these claims could limit our coverage under future insurance policies or cause those policies to become more expensive, which could harm our business, financial condition, and operating results. Recent trends in the product liability and director and officer insurance markets is to exclude matters related to certain classes of drugs. Our policies have been subject to such exclusions which place further potential risk of financial loss on us. Legal fees for litigation-related matters are expensed as incurred and included in the condensed consolidated statements of operations under the selling, general, and administrative expense line item. Commercial Litigation On December 3, 2020, class action complaints were filed against the Company on behalf of putative classes of direct and indirect purchasers of the drug Bystolic. On December 23, 2020, six individual purchasers of Bystolic, CVS, Rite Aid, Walgreen, Kroger, Albertsons, and H-E-B, filed complaints against the Company. On March 15, 2021, the plaintiffs in these actions filed amended complaints. All amended complaints were substantively identical. The plaintiffs in these actions alleged that, beginning in 2012, Forest Laboratories, the manufacturer of Bystolic, entered into anticompetitive agreements when settling patent litigation related to Bystolic with seven potential manufacturers of a generic version of Bystolic: Hetero, Torrent, Alkem/Indchemie, Glenmark, Amerigen, Watson, and various of their corporate parents, successors, subsidiaries, and affiliates. ANI itself was not a party to patent litigation with Forest concerning Bystolic and did not settle patent litigation with Forest. The plaintiffs named the Company as a defendant based on the Company’s January 8, 2020 Asset Purchase Agreement with Amerigen. Under the terms of the 2020 Asset Purchase Agreement, Amerigen agreed to indemnify ANI for certain liabilities relating to Bystolic, including liabilities that arose prior to closing of the asset purchase. The complaints alleged that the 2013 patent litigation settlement agreement between Forest and Amerigen violated federal and state antitrust laws and state consumer protection laws by delaying the market entry of generic versions of Bystolic. Plaintiffs alleged they paid higher prices as a result of delayed generic competition. Plaintiffs sought damages, trebled or otherwise multiplied under applicable law, injunctive relief, litigation costs and attorneys’ fees. The complaints did not specify the amount of damages sought from the Company or other defendants and the Company. The cases were consolidated in the United States District Court for the Southern District of New York. On April 23, 2021, the Company and other defendants filed motions to dismiss the amended complaints. On January 24, 2022, the court dismissed all claims brought by the plaintiffs without prejudice. The court granted the plaintiffs until February 22, 2022 to file amended complaints, which were filed in federal court in the Southern District of New York, on that date. The newly amended complaints contained substantially similar claims. On April 19, 2022, the Company and other defendants filed motions to dismiss the newly amended complaints. After full briefing and oral argument, on February 21, 2023, the court granted the Company and the defendants’ motion to dismiss all actions with prejudice. Plaintiffs filed an appeal in the Second Circuit. On May 13, 2024, the Second Circuit affirmed the district court’s judgment, dismissing plaintiffs’ claims with prejudice. On March 4, 2024, ANI commenced a civil action against CG Oncology, Inc. f/k/a Cold Genesys, Inc. (“CG Oncology”) in the Superior Court of the State of Delaware (“Delaware Action”). ANI’s complaint alleges that, under an Assignment and Technology Transfer Agreement dated as of November 15, 2010 (the “November 2010 Agreement”), CG Oncology is liable to pay ANI a running royalty of 5% of the worldwide net sales of cretostimogene made by CG Oncology or any affiliate or sublicensee thereof; and that in February 2024, CG Oncology wrongfully repudiated its royalty obligation to ANI. On April 2, 2024, CG Oncology filed an answer and counterclaim (the “CGON Answer and Counterclaim”) and concurrently moved for judgment on the pleadings or, in the alternative, for partial summary judgment (the “Motion for Summary Judgment”). CG Oncology’s Motion for Summary Judgment seeks judgment declaring that the November 2010 Agreement does not “oblige CGON to pay royalties after expiration of the latest-running assigned patent.” CG Oncology also seeks judgment awarding compensatory damages and punitive damages on counterclaims for alleged breach of the November 2010 Agreement and for alleged misappropriation of trade secrets under federal and Delaware state law. On April 22 and 25, 2024, ANI filed its reply to CG Oncology’s counterclaims, denying any liability to CG Oncology and asserting additional counterclaims against CG Oncology (“Reply Counterclaims”) for alleged breach of the November 2010 Agreement and, in the alternative, for unjust enrichment. ANI’s Reply Counterclaims seek judgment (i) declaring that, under Section 3.3 of the November 2010 Agreement, CG Oncology is contractually obligated to pay ANI 5% of the worldwide net sales of cretostimogene made by CG Oncology or any affiliate or sublicensee thereof; (ii) dismissing CG Oncology’s counterclaims with prejudice; (iii) awarding ANI compensatory damages as provided by law, including damages grounded in restitution and unjust enrichment; (iv) in the event of a judgment in ANI’s favor on ANI’s fourth counterclaim for unjust enrichment, ordering CG Oncology to re-transfer to ANI ownership of all assets that ANI sold to CG Oncology under the November 2010 Agreement, including, without limitation, all data and documentation comprising IND 12154; and (v) in the event of a judgment in ANI’s favor on ANI’s fourth counterclaim for unjust enrichment, imposing a constructive trust on all fruits of CG0070-related assets that ANI sold to CG Oncology under the November 2010 Agreement including, without limitation, all data and documentation comprising IND 12154 and any other IND that CG Oncology may have for CG0070. On May 15, 2024, CG Oncology filed a reply to ANI’s counterclaims, which generally maintains the positions in the CGON Answer and Counterclaim. The parties are currently engaged in pretrial discovery. On August 22, 2024, the court heard the parties' oral arguments in a hearing on CG Oncology’s Motion for Summary Judgment. The court's decision on the Motion for Summary Judgement is pending. ANI intends to vigorously pursue this matter. On March 5, 2024, a complaint was filed against ANI by Acella Pharmaceuticals, LLC, in the United States District Court of Minnesota, asserting, among other things, false advertising under the Lanham Act, and unfair trade practices and false advertising under Minnesota law, relating to ANI’s natural desiccated thyroid tablets USP. The complaint seeks injunctive relief, actual and consequential damages, disgorgement of profits, and attorneys’ fees and costs. On April 16, 2024, ANI filed an answer to Acella’s complaint, denying all claims, and asserting certain affirmative defenses, and counterclaims against Acella for false advertising of its thyroid product marketed as NP Thyroid® Tablets, under the Lanham Act, common law unfair competition and unfair and deceptive trade practices and false advertising under Minnesota and Georgia law. ANI seeks injunctive relief, compensatory damages, punitive damages and attorneys’ fees and costs. On May 17, 2024, Acella filed a motion to dismiss ANI’s counterclaims. On June 7, 2024, ANI filed an amended answer to Acella’s complaint and counterclaims. Acella filed a motion to dismiss ANI’s amended counterclaims on July 31, 2024. A hearing was held on September 11, 2024 on Acella’s motion to dismiss. The court's decision is pending. The case is currently in fact discovery until February 1, 2025. ANI disputes any liability in this matter and intends to defend this lawsuit vigorously. Patent Litigation On November 21, 2023, a complaint was filed against Novitium and certain other defendants in the case of Harmony Biosciences, LLC, Bioprojet Societe Civile de Recherche and Bioprojet Pharma SAS v. AET Pharma US, Inc., Annora Pharma Private Limited, Novitium Pharma LLC, Zenara Pharma Private Limited and Biophore India Pharmaceuticals Private Limited in the United States District Court for the District of Delaware, asserting, among other things, that Novitium’s proposed pitolisant hydrochloride drug product, which is subject to Novitium’s Abbreviated New Drug Application, infringes certain U.S. patents. The complaint seeks damages, injunctive relief, attorneys’ fees and costs. On January 29, 2024, Novitium filed its answer, denying all allegations and asserting counterclaims of non-infringement and invalidity. On February 16, 2024, plaintiffs filed their answer, denying Novitium’s counterclaims and asserting certain affirmative defenses against Novitium. On April 15, 2024, the court consolidated Novitium’s case and two other cases brought by plaintiffs against Lupin Limited et al, and MSN Pharms. Inc. et al., into one consolidated matter filed in C.A. No. 23-1286-JLH. The case is currently in discovery. The court set a trial date of February 2026. Novitium disputes any liability in this matter. Ranitidine Related Litigation Federal Court Multi District Litigation ANI and Novitium were named as defendants, along with numerous other brand and generic pharmaceutical manufacturers, wholesale distributors, retail pharmacy chains, and repackagers of ranitidine-containing products, in In re: Zantac/Ranitidine NDMA Litigation (MDL No, 2924), filed in the United States District Court for the Southern District of Florida (the “MDL Court”). Plaintiffs allege that defendants failed to disclose and/or concealed the alleged inherent presence of N-Nitrosodimethylamine (or “NDMA”) in brand-name Zantac or generic ranitidine and the alleged associated risk of cancer. While ANI was initially a defendant, the lead plaintiff attorneys voluntarily dismissed ANI as a defendant in the Master Complaint. On July 8, 2021, the MDL Court dismissed all claims by all plaintiffs against the generic drug manufacturers with prejudice , on preemption grounds. The MDL Court also dismissed all claims by all plaintiffs against the brand manufacturers on summary judgment. Plaintiffs appealed the MDL Court’s dismissals to the Eleventh Circuit Court of Appeals. On November 7, 2022, the Eleventh Circuit affirmed the MDL Court’s dismissal of cases brought by third-party payors. The Eleventh Circuit raised questions in the appeals of the other cases about the finality of the MDL Court’s judgments, which were resolved in September 2023. Plaintiffs filed opening briefs on April 10, 2024 and generics defendants filed their response on July 25, 2024. ANI and Novitium dispute any liability in this matter. State Court Personal Injury Litigation ANI and Novitium have also been named as defendants in various state lawsuits. California. The pending cases in California state court naming generic ranitidine manufacturers were transferred to an existing civil case coordination docket for pretrial proceedings (JCCP) in Alameda County. On September 21, 2023, plaintiffs filed a master complaint in the JCCP alleging strict liability, negligent failure to warn and general negligence, but not naming any generic defendants. Plaintiffs filed an amended master complaint on April 29, 2024 and filed a second amended master complaint on July 2, 2024. Defendants filed omnibus demurrers to the complaint. Novitium is named in one case. The court heard arguments for the demurrers on August 22, 2024 and issued its final ruling on August 28, 2024, allowing some counts to survive. The surviving counts as to generic defendants include strict liability (manufacturing defect) and general negligence (storage and transport, failure to warn and product containers). Novitium filed its answer to the second amended master complaint on September 6, 2024. In December 2023, the Keller Postman firm filed approximately 200 individual plaintiff short form complaints that name generic defendants. Novitium is named in 29 of the short form complaints which reference the claims for the master complaint, but Novitium has not been served. ANI is not named. On February 1, 2024, the generic defendants filed an omnibus demurrer challenging the sufficiency of the Keller Postman complaints, largely on the basis of preemption. On April 23, 2024, the California court sustained the demurrer in part, dismissing all design defect claims against the generic defendants with prejudice on preemption grounds, but the court otherwise granted plaintiffs an opportunity for leave to amend their other claims against the generic defendants. Plaintiffs filed amended short form complaints on September 20, 2024 and defendants filed responses on October 6, 2024. Pleadings are now closed and discovery is currently ongoing. Pennsylvania. In September 2022, two complaints were filed naming Novitium as a defendant in Pennsylvania state court, Philadelphia County. On February 16, 2023, the Pennsylvania plaintiffs filed a consolidated long-form complaint against the generic defendants, Plaintiffs v. Actavis, et. al. Civil Action No. 1364. The long-form complaint names Novitium as a defendant. The long form complaint asserts causes of action for negligence, failure to warn, negligent storage and transportation, breach of express warranties, breach of implied warranties, negligent misrepresentation, fraud, strict products liability, wrongful death and survivor actions, and loss of consortium. The complaint includes a prayer for punitive damages. The generic defendants filed their preliminary objections to Plaintiffs’ consolidated long-form generic complaint on March 20, 2023. The court dismissed all claims related to failure to warn/design defects on preemption grounds. The court also sustained the generics’ preliminary objections relating to the counts of strict liability-design defect and breach of implied warranty to the extent Pennsylvania substantive law applies, effectively dismissing the generic defendants from the case unless and until a non-resident plaintiff names a generic in a short form complaint. Out of an abundance of caution, however, the generics, including Novitium, all filed answers to the long form complaint in June 2023. In January 2024, plaintiffs filed short form complaints naming generic defendants, including Novitium in one complaint. Generic defendants filed joint preliminary objections to the short form complaints based on preemption. The deadline for filing responses to these objections has passed. In addition, Novitium was not named in any amended short form complaint filed by plaintiffs ANI and Novitium dispute any liability in these matters.

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Adjustments for chargebacks and other allowances	$ 91,008	$ 97,262
Preferred Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	1,666,667	1,666,667
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Treasury stock, shares at cost	423,936	263,943
Convertible Preferred Stock
Convertible Preferred Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible Preferred Stock, shares authorized	1,666,667	1,666,667
Convertible Preferred Stock, shares issued	25,000	25,000
Convertible Preferred Stock, shares outstanding	25,000	25,000
Common Stock
Common Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, shares authorized	33,333,334	33,333,334
Common Stock, shares issued	21,493,799	20,730,896
Common Stock, shares outstanding	21,069,863	20,466,953
Class C Special Stock
Common Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, shares authorized	781,281	781,281
Common Stock, shares issued	10,864	10,864
Common Stock, shares outstanding	10,864	10,864

RESTRUCTURING CANADA OPERATIONS (Details) $ in Millions		3 Months Ended		9 Months Ended
RESTRUCTURING CANADA OPERATIONS (Details) $ in Millions	Mar. 28, 2024 USD ($)	Sep. 30, 2024 USD ($) facility	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) facility	Sep. 30, 2023 USD ($)	Feb. 16, 2024 USD ($)	Feb. 16, 2024 CAD ($)	Feb. 15, 2024 USD ($)	Feb. 15, 2024 CAD ($)	Dec. 31, 2023 USD ($)
Restructuring
Number of pharmaceutical manufacturing facilities \| facility		3		3
Restructuring activity expense		$ 0	$ 0	$ 0	$ 1,132,000
Assets held for sale		0		0						$ 8,020,000
Disposal Group, Held-for-Sale, Not Discontinued Operations \| Oakville, Ontario Former Manufacturing Facility
Restructuring
Consideration	$ 13,500,000					$ 14,200,000	$ 19.2	$ 14,200,000	$ 19.2
Payment of commissions, taxes and other related costs	700,000
Gain on sale of property	$ 5,300,000
Oakville, Ontario, Canada
Restructuring
Restructuring activity expense		0	$ 0	0	1,100,000
Restructuring accrual		$ 0		$ 0
Assets held for sale										$ 8,000,000.0
Oakville, Ontario, Canada \| Employee Severance
Restructuring
Restructuring activity expense					200,000
Oakville, Ontario, Canada \| Facility Closing
Restructuring
Restructuring activity expense					700,000
Oakville, Ontario, Canada \| Other Restructuring
Restructuring
Restructuring activity expense					$ 200,000

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Net Revenues	$ 148,332	$ 131,829	$ 423,802	$ 355,162
Operating Expenses
Cost of sales (excluding depreciation and amortization)	63,075	48,101	169,930	128,093
Research and development	10,128	11,121	27,935	24,419
Selling, general, and administrative	79,075	42,007	179,917	117,235
Depreciation and amortization	15,748	15,207	45,131	44,597
Contingent consideration fair value adjustment	825	(2,555)	1,274	(559)
Restructuring activities	0	0	0	1,132
Gain on sale of building	0	0	(5,347)	0
Total Operating Expenses, net	168,851	113,881	418,840	314,917
Operating (loss) income	(20,519)	17,948	4,962	40,245
Other (Expense) Income, net
Unrealized gain on investment in equity securities	1,355	0	8,298	0
Interest expense, net	(2,331)	(6,398)	(11,587)	(21,194)
Other expense, net	(2,535)	(39)	(2,655)	(126)
Loss on extinguishment of debt	(7,468)	0	(7,468)	0
(Loss) Income Before Income Tax (Benefit) Expense	(31,498)	11,511	(8,450)	18,925
Income tax (benefit) expense	(7,332)	1,571	(204)	1,301
Net (Loss) Income	(24,166)	9,940	(8,246)	17,624
Dividends on Series A Convertible Preferred Stock	(406)	(406)	(1,219)	(1,219)
Net (Loss) Income Available to Common Shareholders	$ (24,572)	$ 9,534	$ (9,465)	$ 16,405
Basic and Diluted (Loss) Income Per Share:
Basic (Loss) Income Per Share (in dollars per share)	$ (1.27)	$ 0.46	$ (0.49)	$ 0.84
Diluted (Loss) Income Per Share (in dollars per share)	$ (1.27)	$ 0.45	$ (0.49)	$ 0.83
Basic Weighted-Average Shares Outstanding (in shares)	19,404	18,883	19,275	17,663
Diluted Weighted-Average Shares Outstanding (in shares)	19,404	19,125	19,275	17,823

BUSINESS COMBINATION - Business acquisitions, by acquisition (Details) - Alimera Sciences, Inc $ / shares in Units, shares in Thousands, $ in Thousands	Sep. 16, 2024 USD ($) $ / shares shares
Business Acquisition [Line Items]
Alimera common shares outstanding (in shares) \| shares	53,971
Alimera warrants outstanding after exercise (in shares) \| shares	989
Alimera common shares and warrants outstanding (in shares) \| shares	54,960
Cash consideration per share (in dollars per share) \| $ / shares	$ 5.50
Cash consideration for Alimera Common Stock	$ 302,280
Repayment of Alimera Debt	78,540
Payment of Alimera transaction costs	20,172
Cash settlement for pre-acquisition equity awards	9,535
Fair value of CVRs	8,322
Total Merger Consideration	$ 418,849

NEW CREDIT AGREEMENT (Tables)

9 Months Ended

Sep. 30, 2024

Debt Disclosure [Abstract]

Schedule of carrying value of the current and non-current components of the term loan

The carrying value of the current and non-current components of the Term Facility as of September 30, 2024 and December 31, 2023 are:


	Current
(in thousands)	September 30, 2024		December 31, 2023
Current borrowing on debt	$	—	$	3,000
Deferred financing costs	—		(2,150)
Current debt, net of deferred financing costs	$	—	$	850


	Non-Current
(in thousands)	September 30, 2024		December 31, 2023
Non-current borrowing on debt	$	—	$	291,000
Deferred financing costs	—		(6,181)
Non-current debt, net of deferred financing costs and current component	$	—	$	284,819

The carrying value of the current and non-current components of the New Credit Facility as of September 30, 2024 and December 31, 2023 are:


	Current
(in thousands)	September 30, 2024		December 31, 2023
Current borrowing on debt	$	8,125	$	—
Deferred financing costs	(973)		—
Current debt, net of deferred financing costs	$	7,152	$	—


	Non-Current
(in thousands)	September 30, 2024		December 31, 2023
Non-current borrowing on debt	$	316,875	$	—
Deferred financing costs	(3,957)		—
Non-current debt, net of deferred financing costs and current component	$	312,918	$	—

Schedule of contractual maturity of term loan and DDTL

The contractual maturity of the Term Loan A is as follows for the period ending:


(in thousands)	New Term Facility
2024 (remainder of the year)	$	2,031
2025	10,156
2026	18,281
2027	24,375
2028	24,375
2029	245,782
Total	$	325,000

Schedule of components of total interest expense related to the notes and term loan


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	2,883	$	7,864	$	16,644	$	22,834
Amortization of deferred financing costs	295		591		1,477		1,773
Capitalized interest	(138)		(142)		(401)		(440)
	$	3,040	$	8,313	$	17,720	$	24,167

Extinguishment of the Credit Facility


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	530	$	—	$	530	$	—
Amortization of deferred financing costs	49		—		49		—
	$	579	$	—	$	579	$	—


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	969	$	—	$	969	$	—
Amortization of finance fees	281		—		281		—
	$	1,250	$	—	$	1,250	$	—

- Definition

+ References

+ Details

EARNINGS PER SHARE - Schedule of diluted earnings per share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Basic
Net (loss) income available to common shareholders, Basic	$ (24,572)	$ 9,534	$ (9,465)	$ 16,405
Earnings allocated to participating securities, Basic	0	(891)	0	(1,629)
Net (loss) income available to common shareholders, Basic	(24,572)	8,643	(9,465)	14,776
Diluted
Net (loss) income available to common shareholders, Diluted	(24,572)	9,534	(9,465)	16,405
Earnings allocated to participating securities, Diluted	0	(881)	0	(1,615)
Net (loss) income available to common shareholders, Diluted	$ (24,572)	$ 8,653	$ (9,465)	$ 14,790
Basic
Basic Weighted-Average Shares Outstanding (in shares)	19,404	18,883	19,275	17,663
Diluted
Dilutive effect of common stock options, ESPP, and performance stock units (in shares)	0	242	0	160
Diluted Weighted-Average Shares Outstanding (in shares)	19,404	19,125	19,275	17,823
Basic
(Loss) earnings per share, Basic (in dollars per share)	$ (1.27)	$ 0.46	$ (0.49)	$ 0.84
Diluted
(Loss) earnings per share, Diluted (in dollars per share)	$ (1.27)	$ 0.45	$ (0.49)	$ 0.83

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2024

Share-Based Payment Arrangement [Abstract]

Summary of allocated expense

The following table summarizes ESPP expense incurred under the 2016 Employee Stock Purchase Plan and included in our accompanying unaudited interim condensed consolidated statements of operations:


(in thousands)	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Selling, general, and administrative	$	142	$	109	$	418	$	251
Cost of sales	35		16		95		46
Research and development	18		14		42		33
Total	$	195	$	139	$	555	$	330

The following table summarizes stock-based compensation expense incurred under the Amended 2022 Stock Plan and Inducement Grants included in the accompanying unaudited interim condensed consolidated statements of operations:


(in thousands)	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Selling, general, and administrative	$	6,582	$	4,914	$	19,883	$	13,588
Research and development	423		225		1,029		638
Cost of sales	283		166		816		475
Total	$	7,288	$	5,305	$	21,728	$	14,701

Summary of stock option and restricted stock activity

A summary of stock options (including Inducement Grants), RSA, and PSU activity under the Amended 2022 Stock Plan and Inducement Grants during the nine months ended September 30, 2024 and 2023 is presented below:


(in thousands)	Options	PSUs	RSAs
Outstanding at December 31, 2022	907	—	1,141
Granted	3	85	648
Options Exercised/RSAs Vested	(151)	—	(369)	(1)
Forfeited	(28)	(1)	(76)
Outstanding at September 30, 2023	731	84	1,344

Outstanding at December 31, 2023	689	84	1,351
Granted	—	74	669
Options Exercised/RSAs Vested	(57)	—	(467)	(2)
Forfeited	(1)	—	(60)
Outstanding at September 30, 2024	631	158	1,493

______________________________________________

(1)Includes 111 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $4.8 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets.

(2)Includes 160 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $10.6 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets.

GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)		3 Months Ended		9 Months Ended
	Sep. 16, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets		$ 13,900,000	$ 13,300,000	$ 39,800,000	$ 39,000,000.0
Impairment		0	0	0	0
Impairment of indefinite lived intangible assets		$ 0	$ 0	$ 0	$ 0
Alimera Sciences, Inc
Finite-Lived Intangible Assets [Line Items]
Remaining estimated useful lives		12 years		12 years
Alimera Sciences, Inc \| YUTIQ
Finite-Lived Intangible Assets [Line Items]
Remaining estimated useful lives	12 years
Intangible assets acquired	$ 170,000	$ 170,000,000
Alimera Sciences, Inc \| ILUVIEN
Finite-Lived Intangible Assets [Line Items]
Remaining estimated useful lives	12 years
Intangible assets acquired	$ 230,000	$ 230,000,000
Minimum
Finite-Lived Intangible Assets [Line Items]
Remaining estimated useful lives		7 years		7 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Remaining estimated useful lives		12 years		12 years

STOCK-BASED COMPENSATION - Narrative (Details) - $ / shares			9 Months Ended
	Feb. 14, 2024	Feb. 28, 2023	Sep. 30, 2024	Sep. 30, 2023
Performance-Based Restricted Stock Units
Share-based Compensation
Performance period			3 years
Percentage of awards			50.00%
Vesting period			3 years
Maximum potential to vest percentage		200.00%	200.00%
Maximum potential to vest (in shares)		83,942
Grate date fair value (in dollars per share)	$ 56.10	$ 41.84
Estimate number of shares percentage			100.00%
Market Performance-Based Restricted Stock Units
Share-based Compensation
Percentage of awards			50.00%
Vesting period			3 years
Maximum potential to vest percentage		200.00%
Maximum potential to vest (in shares)		83,942
Grate date fair value (in dollars per share)	$ 85.65	$ 68.65
Estimate number of shares percentage			100.00%
PSUs
Share-based Compensation
Performance period	3 years
Granted (in shares)	73,588		74,000	85,000
PSUs \| Officer
Share-based Compensation
Granted (in shares)	66,433

BUSINESS COMBINATION - Pro-forma activity (Details) - Alimera Sciences, Inc - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Business Acquisition [Line Items]
Net revenues	$ 162,700	$ 155,193	$ 409,610	$ 488,180
Net (loss) income	$ (18,749)	$ 2,327	$ (44,164)	$ (17,754)

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2024	Nov. 01, 2024
Document Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-31812
Entity Registrant Name	ANI PHARMACEUTICALS, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	58-2301143
Entity Address, Address Line One	210 Main Street West
Entity Address, City or Town	Baudette
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	56623
City Area Code	218
Local Phone Number	634-3500
Title of 12(b) Security	Common Stock
Trading Symbol	ANIP
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001023024
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment flag	false
Common Stock
Document Information
Entity Common Stock, Shares Outstanding		21,017,775
Class C Special Stock
Document Information
Entity Common Stock, Shares Outstanding		10,864

STOCK-BASED COMPENSATION

9 Months Ended

Sep. 30, 2024

Share-Based Payment Arrangement [Abstract]

STOCK-BASED COMPENSATION

Employee Stock Purchase Plan

In July 2016, the Company commenced administration of the ANI Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan. As of September 30, 2024, the Company had 0.1 million shares of common stock available under the ESPP. Under the ESPP, participants can purchase common shares of the Company’s stock at a 15% discount on the lowest share price on the first day of the purchase period or the last day of the purchase period.

The following table summarizes ESPP expense incurred under the 2016 Employee Stock Purchase Plan and included in our accompanying unaudited interim condensed consolidated statements of operations:


(in thousands)	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Selling, general, and administrative	$	142	$	109	$	418	$	251
Cost of sales	35		16		95		46
Research and development	18		14		42		33
Total	$	195	$	139	$	555	$	330

Stock Incentive Plan

During the 2024 Annual Meeting of Stockholders held on May 21, 2024, the stockholders of the Company approved an amendment to the Amended and Restated Stock Incentive Plan (the “2022 Plan”) (such amendment, the “2024 Stock Plan Amendment” and the 2022 Plan, after giving effect to the 2024 Stock Plan Amendment, the “Amended 2022 Stock Plan”). Subject to adjustment, the 2024 Stock Plan Amendment authorizes the issuance of an additional 1,610,000 shares.

As of September 30, 2024, 1.9 million shares of common stock were available for issuance under the Amended 2022 Stock Plan.

Stock Options

Outstanding stock options to purchase shares of common stock are granted to employees and consultants generally vest over a period of four years and have 10-year contractual terms. Outstanding stock options granted to non-employee directors generally vest over a period of one to four years and have 10-year contractual terms.

From time to time, stock options are granted to employees through an inducement grant outside of the Amended 2022 Stock Plan to induce prospective employees to accept employment with the Company (the “Inducement Grants”). The options are granted at an exercise price equal to the fair market value of a share of common stock on the respective grant date and are generally exercisable in four equal annual installments beginning on the first anniversary of the respective grant date. The grants are made pursuant to inducement grants outside of our stockholder approved equity plan as permitted under the Nasdaq Stock Market listing rules.

Restricted Stock Awards

Restricted stock awards (“RSAs”) granted to employees generally vest over a period of four years and RSAs granted to non-officer directors generally vest over a period of one year.

During the vesting period, the recipient of the RSAs has full voting rights as a stockholder and would receive dividends, if declared, even though the restricted stock remains subject to transfer restrictions and will generally be forfeited upon termination of the officer prior to vesting. The fair value of each RSA is based on the market value of our stock on the date of grant. Upon vesting, unrestricted shares of common stock are delivered to employees and directors.

Performance-Based Restricted Stock Units

February 28, 2023 Performance-Based Restricted Stock Units Grant

Awards may also be issued in the form of Performance Stock Units (“PSUs”). PSUs represent the right to receive an amount of cash, a number of shares of common stock or a combination of both, contingent upon the achievement of specified performance objectives during a specified performance period. PSUs granted to date vest over a three-year performance period. On February 28, 2023, as part of the Company’s equity compensation program, we granted PSUs to certain executives. Of these PSUs, 50% were market performance-based restricted stock units (“MPRSUs”), vesting of which is contingent upon the Company meeting certain total shareholder return (“TSR”) levels as compared to a select peer group over the over three years starting January 1, 2023. The MPRSUs are also subject to the recipient’s continued employment or service through December 31, 2025. The MPRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (83,942 shares, net of forfeitures) based on TSR performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The estimated grant date fair value per share of the MPRSUs was $68.65 and was calculated using a Monte Carlo simulation model. These MPRSUs are included at 100% of the estimate number of shares at the end of the three-year performance period and are reflected under “Granted” in the table below.

The other 50% of the PSUs were performance based restricted stock units (“PRSUs”), vesting of which is contingent upon the Company meeting certain adjusted non-GAAP year-on-year EBITDA growth rates over the over three years starting January 1, 2023. The PRSUs are also subject to the recipient’s continued employment or service through December 31, 2025. The PRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (83,942 shares, net of forfeitures) based on adjusted non-GAAP year-on-year EBITDA growth rates. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The Company analyzed progress on the performance goals to assess the likelihood of achievement. The estimated grant date fair value per share of the PRSUs was $41.84 based on the closing price of the stock on the date of grant. These PRSUs are included at 100% of the estimated number of shares at the end of the three-year performance period and are reflected under “Granted” in the table below.

February 14, 2024 Performance-Based Restricted Stock Units Grant

On February 14, 2024, the Company granted 73,588 PSUs to officers and employees of the Company under the 2022 Plan (66,433 to officers of the Company). PSU performance will be measured over a three-year performance period from January 1, 2024 through December 31, 2026 and will cliff-vest contingent upon the achievement of specified performance objectives. Of these PSUs, 50% were MPRSUs, vesting of which is contingent upon the Company meeting certain TSR levels as compared to a select peer group over the over three years starting January 1, 2024, and 50% of the PSUs were PRSUs, vesting of which is contingent upon the Company meeting certain adjusted non-GAAP year-on-year EBITDA growth rates over the over three years starting January 1, 2024. Both the MPRSUs and the PRSUs have a maximum potential to vest at 200%.

The estimated grant date fair value per share of the MPRSUs was $85.65 and was calculated using a Monte Carlo simulation model. These MPRSUs are included at 100% of the estimate number of shares at the end of the three-year performance period and are reflected under “Granted” in the table below.

The estimated grant date fair value per share of the PRSUs was $56.10 based on the closing price of the stock on the date of grant. These PRSUs are included at 100% of the estimated number of shares at the end of the three-year performance period and are reflected under “Granted” in the table below.


(in thousands)	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Selling, general, and administrative	$	6,582	$	4,914	$	19,883	$	13,588
Research and development	423		225		1,029		638
Cost of sales	283		166		816		475
Total	$	7,288	$	5,305	$	21,728	$	14,701


(in thousands)	Options	PSUs	RSAs
Outstanding at December 31, 2022	907	—	1,141
Granted	3	85	648
Options Exercised/RSAs Vested	(151)	—	(369)	(1)
Forfeited	(28)	(1)	(76)
Outstanding at September 30, 2023	731	84	1,344

Outstanding at December 31, 2023	689	84	1,351
Granted	—	74	669
Options Exercised/RSAs Vested	(57)	—	(467)	(2)
Forfeited	(1)	—	(60)
Outstanding at September 30, 2024	631	158	1,493

______________________________________________

MEZZANINE AND STOCKHOLDERS' EQUITY (Details) $ / shares in Units, $ in Millions	Nov. 19, 2021 USD ($) tradingDay $ / shares shares	Mar. 08, 2021 USD ($) $ / shares shares	Sep. 30, 2024 vote $ / shares shares	Jun. 30, 2024 shares	Dec. 31, 2023 $ / shares shares	Sep. 30, 2023 shares	Jun. 30, 2023 shares	Dec. 31, 2022 shares
Temporary Equity [Line Items]
Preferred Stock, shares authorized			1,666,667		1,666,667
Preferred Stock, par value (in dollars per share) \| $ / shares			$ 0.0001		$ 0.0001
Common Stock
Temporary Equity [Line Items]
Common Stock, shares authorized			33,333,334		33,333,334
Common Stock, par value (in dollars per share) \| $ / shares			$ 0.0001		$ 0.0001
Common Stock, shares issued			21,493,799		20,730,896
Common Stock, shares outstanding			21,069,863		20,466,953
Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock outstanding (shares)			25,000	25,000	25,000	25,000	25,000	25,000
PIPE Shares \| Convertible Preferred Stock
Temporary Equity [Line Items]
Temporary stock issued (in shares)	25,000	25,000
Temporary stock issued (in dollars per share) \| $ / shares	$ 1,000	$ 1,000
Temporary stock issued, value \| $	$ 25.0	$ 25.0
Shares accrue dividends rate	6.50%
Shares conversion price (in dollars per share) \| $ / shares	$ 41.47
Minimum conversion period	2 years
Threshold number of trading days \| tradingDay	20
Number of consecutive trading days \| tradingDay	30
Maximum percentage of conversion price	170.00%
Convertible, shares issuable			602,901
Common Stock
Temporary Equity [Line Items]
Common Stock, shares authorized			33,300,000
Common Stock, par value (in dollars per share) \| $ / shares			$ 0.0001
Common Stock, shares outstanding			21,494,000	21,476,000	20,731,000	20,654,000	20,536,000	17,644,000
Class C Special Stock
Temporary Equity [Line Items]
Common Stock, shares authorized			800,000
Common Stock, par value (in dollars per share) \| $ / shares			$ 0.0001
Common Stock, shares issued			11,000		11,000
Common Stock, shares outstanding			11,000		11,000
Vote per share \| vote			1
Exchange per share			1
Common Stock, conversion price (in dollars per share) \| $ / shares			$ 90.00

EARNINGS PER SHARE

9 Months Ended

Sep. 30, 2024

Earnings Per Share [Abstract]

EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is calculated by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options, shares to be purchased under the 2016 Employee Stock Purchase Plan (“ESPP”), and performance stock units, using the more dilutive of the treasury stock or the two-class method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share.

Unvested restricted shares and Series A convertible preferred stock shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic and diluted earnings (loss) per share excludes from the numerator net income (but not net loss) attributable to the unvested restricted shares and the common shares assumed converted from the preferred shares and excludes the impact of those shares from the denominator. The Company’s participating securities do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. As the Company has reported a net loss for the three and nine months ended September 30, 2024, diluted net loss per share attributable to common shareholders is the same as basic net loss per share attributable to common shareholders for this period.

Earnings per share for the three and nine months ended September 30, 2024 and 2023 are calculated for basic and diluted earnings per share as follows:


	Basic				Diluted				Basic				Diluted
(in thousands, except per share amounts)	Three Months Ended September 30,				Three Months Ended September 30,				Nine Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023		2024		2023		2024		2023
Net (loss) income available to common shareholders	$	(24,572)	$	9,534	$	(24,572)	$	9,534	$	(9,465)	$	16,405	$	(9,465)	$	16,405
Earnings allocated to participating securities	—		(891)		—		(881)		—		(1,629)		—		(1,615)
Net (loss) income available to common shareholders	$	(24,572)	$	8,643	$	(24,572)	$	8,653	$	(9,465)	$	14,776	$	(9,465)	$	14,790
Basic Weighted-Average Shares Outstanding	19,404		18,883		19,404		18,883		19,275		17,663		19,275		17,663
Dilutive effect of common stock options, ESPP, and performance stock units					—		242						—		160
Diluted Weighted-Average Shares Outstanding					19,404		19,125						19,275		17,823

(Loss) earnings per share	$	(1.27)	$	0.46	$	(1.27)	$	0.45	$	(0.49)	$	0.84	$	(0.49)	$	0.83

The number of shares of potentially dilutive securities excluded from the computation of diluted net loss per share attributable to common stockholders was 2.7 million and 2.3 million for the three and nine months ended September 30, 2024, respectively, because including them would have been anti-dilutive. The Company has also excluded approximately 4.3 million shares from the computation of diluted net loss per share for the three and nine months ended September 30, 2024, representing the maximum number of conversion shares from the Convertible Senior Notes.

The number of anti-dilutive shares, which have been excluded from the computation of diluted earnings per share, was 2.1 million and 2.4 million for the three and nine months ended September 30, 2023, respectively.

FAIR VALUE DISCLOSURES

9 Months Ended

Sep. 30, 2024

Fair Value Disclosures [Abstract]

FAIR VALUE DISCLOSURES

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value.

The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of our funds. The fair value of short-term financial instruments (primarily accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current liabilities) approximate their carrying values because of their short-term nature. The Term Facility, which was extinguished on August 13, 2024, and the New Credit Facility bear interest rates that fluctuates with the changes in SOFR and because the variable interest rates approximate market borrowing rates available to us, we believe the carrying values of these borrowings approximated their fair values at September 30, 2024.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Alimera Contingent Value Rights Agreement

On September 16, 2024, prior to consummation of the Alimera Acquisition, the Company entered into a CVR pursuant to which holders of Alimera Common Stock, as well as holders of Alimera Warrants, Alimera Options, Alimera PSUs, Alimera RSAs and Alimera RSUs, may become entitled to contingent cash payments per CVR (each, a “Milestone Payment”), such payments being contingent upon, and subject to, the achievement of: (i) $140.0 million in net revenue (the “2026 Milestone”) on third party sales of ILUVIEN and YUTIQ for the Company’s 2026 fiscal year (the “2026 Net Revenue”) and/or (ii) $160.0 million in net revenue (the “2027 Milestone” and together with the 2026 Milestone, the “Milestones”) on third party sales of ILUVIEN and YUTIQ for the Company’s 2027 fiscal year (the “2027 Net Revenue”). Each CVR entitles the holder (the “Holder”) to receive a Milestone Payment upon satisfaction of the applicable Milestones. The Milestone Payment for each CVR will equal the product (rounded to the nearest 1/100 of $0.01) of (i) $0.25 multiplied by a fraction (not exceeding one), the numerator of which is the amount, if any, by which the 2026 Net Revenue exceeds $140.0 million and the denominator of which is $10.0 million (subject to adjustment for the exercise price of applicable Alimera Options) and/or (ii) $0.25 multiplied by a fraction (not exceeding one), the numerator of which is the amount, if any, by which the 2027 Net Revenue exceeds $160.0 million and the denominator of which is $15.0 million (subject to adjustment for the exercise price of applicable Alimera Options).

If a Milestone is attained, the distributions in respect of the CVRs will be made on or prior to the date that is fifteen (15) business days following the filing by the Company of its audited financial statements with the SEC on Form 10-K in respect of the applicable year in which such Milestone has been achieved, and will be subject to a number of deductions, exceptions and limitations, including, but not limited to, certain taxes.

The fair value of the CVR liability is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. The Company utilized a Monte Carlo simulation model to estimate the fair value of the CVR liability. For each simulated path of future revenue, the payments to the CVR holders were calculated based on the contractual terms of the rights. The average payments from all simulated paths were then discounted to present value at an estimated cost of debt. The CVR liability had an estimated fair value of $8.7 million as of September 30, 2024, and is classified as non-current contingent consideration in the Company's unaudited interim condensed consolidated balance sheet.

The following table presents the changes in the CVR balances classified as Level 3 for the three and nine months ended September 30, 2024 and 2023:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Beginning balance	$	—	$	—	$	—	$	—
CVR Agreement	8,700		—		8,700		—
Ending balance	$	8,700	$	—	$	8,700	$	—

Money Market Funds

Money market funds are readily convertible into cash and the net asset value of each fund on the last day of the reporting period is used to determine its fair value. Money market funds are included in Cash and cash equivalents within the Consolidated Balance Sheet, and is classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company does not adjust the quoted market price for such financial instruments. The fair value of the money market funds as of September 30, 2024 was approximately $83.3 million.

Interest Rate Swap

The fair value of the interest rate swap is estimated based on the present value of projected future cash flows using the SOFR forward rate curve (see Note 6 New Credit Agreement” to the Notes to Condensed Consolidated Financial Statements). The model used to value the interest rate swap includes inputs of readily observable market data, a Level 2 input. As described in further detail in Note 8 “Derivative Financial Instrument and Hedging Activity” to the Notes to Condensed Consolidated Financial Statements. The model used to value the interest rate swap includes inputs of readily observable market data, a Level 2 input. As described in further detail in Note 8, the fair value of the interest rate swap was $3.6 million as of September 30, 2024, and was classified as a non-current asset.

CG Oncology Equity Securities

The Company currently holds 219,925 shares of common stock in CG Oncology (Nasdaq: CGON). The Company accounts for its investment in CG Oncology equity securities as an equity investment with a readily determinable fair value, as the securities are publicly traded on the Nasdaq Global Select Market. The fair value of the equity securities is based on its closing price on the Nasdaq and is classified within Level 1 of the fair value hierarchy because the equity securities are valued using quoted market prices. The Company does not adjust the quoted market price for such financial instruments. The fair value of the CG Oncology equity securities as of September 30, 2024 was approximately $8.3 million based on a closing market price of $37.73 on September 30, 2024. This amount is classified on the unaudited condensed consolidated statements of operations as Unrealized gain on investment in equity securities for the nine months ended September 30, 2024. Between 2013 and 2023, CG Oncology securities held by the Company were valued at zero under U.S. GAAP.

Novitium Contingent Consideration

In connection with the acquisition of Novitium, the Company may pay up to $46.5 million in additional consideration related to the achievement of certain milestones, such as milestones on gross profit of Novitium portfolio products over a 24-month period, regulatory filings completed during this 24-month period, and a percentage of net profits on certain products that are launched in the future.

The discounted cash flow method used to value this contingent consideration includes inputs which are classified as Level 3 inputs, as the inputs are not based on readily available market data.

Pursuant to the terms of the Novitium Merger Agreement, on December 12, 2023, the Company paid $12.5 million of cash consideration to the Company Members, defined as the holders of Novitium ownership interests in the Novitium Merger Agreement, as the holders of Novitium ownership interests, for the achievement of the “ANDA Filing Earn-Out,” as defined in the Agreement (Note 15 “Commitments and Contingencies” to the Notes to Condensed Consolidated Financial Statements). Furthermore, on February 22, 2024, the Company paid $12.5 million to Company Members of Novitium upon the achievement of the “Gross Profit Earn-Out,” as defined in the Agreement (Note 17 “Related Party Transactions” to the Notes to Condensed Consolidated Financial Statements).

The fair value of the contingent consideration was approximately $12.8 million and $24.0 million as of September 30, 2024 and December 31, 2023, respectively, and is reflected as a current and non-current accrued contingent consideration liability in the unaudited interim condensed consolidated balance sheets.

The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs as of September 30, 2024:

Payment Type

Valuation Technique

Unobservable Input

Assumptions

Profit-based milestone payments

Probability-weighted discounted cash flow

Discount rate

12%

Projected fiscal year of payment

2025-2035

The following table presents the changes in contingent consideration balances classified as Level 3 for the three and nine months ended September 30, 2024 and 2023:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Beginning balance	$	11,933	$	37,054	$	23,984	$	35,058
Payment of Gross-Profit earn-out	—		—		(12,500)		—
Change in fair value	825		(2,555)		1,274		(559)
Ending balance	$	12,758	$	34,499	$	12,758	$	34,499

Accrued Licensor Payments

On May 17, 2023, Alimera entered into a product rights agreement with EyePoint Parent which granted Alimera an exclusive and sublicensable right and license under EyePoint Parent’s and its affiliates’ interest in certain of EyePoint Parent’s and its affiliates’ intellectual property to develop, manufacture, sell, commercialize and otherwise exploit certain products, including YUTIQ, for the treatment and prevention of uveitis in the entire world, except Europe, the Middle East and Africa, where the Company already has such rights pursuant to the New Collaboration Agreement, and except for China, Hong Kong, Macau, Taiwan, Brunei, Burma (Myanmar), Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, the Philippines, Singapore, South Korea, Thailand and Vietnam, where Ocumension holds a license from EyePoint Parent. Pursuant to the agreement, Alimera paid EyePoint Parent an upfront payment of $75.0 million and has also made three quarterly guaranteed payments to EyePoint Parent totaling $5.6 million during 2024, with one remaining payment of $1.9 million due at December 31, 2024.

The Company will also pay royalties to EyePoint Parent from 2025 to 2028 at a percentage of mid-to-low double digits of annual U.S. net sales of certain products (including YUTIQ and ILUVIEN) in excess of certain thresholds, beginning at $70.0 million in 2025, increasing annually thereafter. Upon making the quarterly payments in the aggregate amount of $7.5 million in 2024, the licenses and rights granted to the Company will automatically become perpetual and irrevocable.

For the quarter ended September 30, 2024, the Company paid the third quarterly payment of $1.9 million, with $1.9 million due at December 31, 2024. The present value of the remaining 2024 quarterly payments and the present value of estimated royalties payable to EyePoint Parent for years 2025 to 2028 will continue to be revalued at an appropriate discount rate for the Company at each reporting date until they are settled. The fair value of the remaining future payments as of September 30, 2024 was approximately $23.1 million.

The following table presents our financial assets and liabilities accounted for at fair value on a recurring basis as of September 30, 2024 and December 31, 2023, by level within the fair value hierarchy:


(in thousands) Description	Fair Value at September 30, 2024		Level 1		Level 2		Level 3
Assets
Money Market Fund	$	83,304	$	83,304	$	—	$	—
Interest rate swap	$	3,556	$	—	$	3,556	$	—
CG Oncology - Investment in equity securities	$	8,298	$	8,298	$	—	$	—
Liabilities
Contingent consideration, Novitium	$	12,758	$	—	$	—	$	12,758
Contingent Value Rights, Alimera	$	8,700	$	—	$	—	$	8,700
Accrued licensor payment	$	23,125	$	—	$	—	$	23,125


Description	Fair Value at December 31, 2023		Level 1		Level 2		Level 3
Assets
Money Market Fund	$	191,841	$	191,841	$	—	$	—
Interest rate swap	$	6,236	$	—	$	6,236	$	—
Liabilities
Contingent consideration	$	23,984	$	—	$	—	$	23,984

Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

There are no financial assets or liabilities that are measured at fair value on a non-recurring basis.

Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

There are no non-financial assets or liabilities that are measured at fair value on a recurring basis.

Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

Long-lived assets, including property, plant, and equipment, right-of-use (“ROU”) assets, intangible assets, and goodwill, are measured at fair value on a non-recurring basis, and no such fair value impairment was recognized in the three and nine months ended September 30, 2024 and 2023.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands			1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	Dec. 27, 2023 USD ($)	Dec. 03, 2020 plaintiff	Jan. 31, 2024 claim	Dec. 31, 2023 claim	Sep. 30, 2022 claim	Sep. 30, 2024 USD ($) product	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) product	Sep. 30, 2023 USD ($)	Dec. 31, 2012 manufacturer	Mar. 04, 2024	Apr. 30, 2023
COMMITMENTS AND CONTINGENCIES
Lease term												5 years
Number of products marketed without approved NDAs or ANDAs \| product						4		4
Total net revenues						$ 148,332	$ 131,829	$ 423,802	$ 355,162
Payment for acquired intangible assets								631	7,143
Number of plaintiffs \| plaintiff		6
Number of potential manufacturers \| manufacturer										7
Royalty percentage											5.00%
Net sales percentage											5.00%
Number of complaints filed \| claim			1	200	2
Alvogen Inc \| Product Intellectual Property
COMMITMENTS AND CONTINGENCIES
Payment for acquired intangible assets	$ 2,000
Novitium
COMMITMENTS AND CONTINGENCIES
Number of complaints filed \| claim				29
Unapproved Products
COMMITMENTS AND CONTINGENCIES
Total net revenues						5,500	9,200	16,400	16,400
Unapproved Products \| Contract Customer
COMMITMENTS AND CONTINGENCIES
Total net revenues						$ 100	$ 100	$ 100	$ 1,100

NEW CREDIT AGREEMENT - Facility components (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Current debt, net of deferred financing costs	$ 7,152	$ 850
Non-current debt, net of deferred financing costs and current component	312,918	284,819
Line of Credit \| New Credit Agreement
Debt Instrument [Line Items]
Current borrowing on debt	8,125	0
Deferred financing costs	(973)	0
Current debt, net of deferred financing costs	7,152	0
Non-current borrowing on debt	316,875	0
Deferred financing costs	(3,957)	0
Non-current debt, net of deferred financing costs and current component	$ 312,918	$ 0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

INVENTORIES - Narrative (Details) $ in Millions	9 Months Ended
INVENTORIES - Narrative (Details) $ in Millions	Sep. 30, 2024 USD ($)
Alimera Sciences, Inc
Inventory [Line Items]
Business combination, provisional information, initial accounting incomplete, adjustment, inventory	$ 11.7
Supplier Concentration Risk \| Cost of Goods and Service Benchmark \| One Supplier
Inventory [Line Items]
Concentration risk, percentage	17.00%

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash Flows From Operating Activities
Net (loss) income	$ (8,246)	$ 17,624
Adjustments to reconcile net (loss) income to net cash and cash equivalents provided by operating activities:
Stock-based compensation	22,283	15,031
Deferred taxes	(4,383)	(3,394)
Depreciation and amortization	45,131	44,597
Unrealized gain on investment in equity securities	(8,298)	0
Non-cash operating lease expense	1,134	888
Non-cash interest	319	2,970
Contingent consideration fair value adjustment	1,274	(559)
Gain on sale of building	(5,347)	0
Loss on extinguishment of debt	(7,468)	0
Amortization of inventory step up	3,224	0
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable, net	4,426	(13,404)
Inventories	(20,612)	(1,236)
Prepaid expenses and other assets	3,822	(636)
Accounts payable	7,300	4,772
Accrued royalties	7,171	(2,668)
Prepaid income taxes	(14,268)	4,426
Accrued government rebates	(1,475)	(51)
Returned goods reserve	4,296	(1,961)
Accrued expenses, accrued compensation, and other	2,938	7,820
Net Cash and Cash Equivalents Provided by Operating Activities	48,157	74,219
Cash Flows From Investing Activities
Acquisition of Alimera, net of cash acquired	(393,079)	0
Acquisition of product rights, intangible assets, and other related assets	(631)	(7,143)
Acquisition of property and equipment, net	(13,842)	(6,589)
Proceeds from the sale of building	13,514	0
Net Cash and Cash Equivalents Used in Investing Activities	(394,038)	(13,732)
Cash Flows From Financing Activities
Proceeds from convertible notes	316,250	0
Proceeds from term loan	325,000	0
Purchase of capped call transaction	(40,575)	0
Repayment on borrowings under credit agreement	(292,500)	0
Debt issuance costs	(15,376)	0
Principal payments on borrowings under credit agreements	(1,500)	(2,250)
Series A convertible preferred stock dividends paid	(1,219)	(1,219)
Proceeds from stock option exercises and ESPP purchases	4,788	7,027
Proceeds from public offering	0	80,555
Treasury stock purchases for restricted stock vests	(10,641)	(4,756)
Payments on contingent consideration	(12,500)	0
Payment of accrued licensor payments	(1,875)	0
Net Cash and Cash Equivalents Provided by Financing Activities	269,852	79,357
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	(75)	0
Net Change in Cash, Cash Equivalents, and Restricted Cash	(76,104)	139,844
Cash, cash equivalents, and restricted cash, beginning of period	221,121	53,234
Cash. cash equivalents, and restricted cash end of period	145,017	193,078
Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized	19,232	23,426
Cash paid for income taxes	17,214	930
Right-of-use assets obtained in exchange for lease obligations	0	4,499
Supplemental non-cash investing and financing activities:
Property and equipment purchased and included in accounts payable	635	247
Purchase consideration for Alimera Acquisition	(16,523)	0
Accrued deferred financing costs	$ (1,976)	$ 0

STOCK-BASED COMPENSATION - Non-option activity (Details) - USD ($) $ in Thousands		9 Months Ended
	Feb. 14, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Non-option Shares
Treasury stock value		$ 20,722		$ 10,081
PSUs
Non-option Shares
Outstanding at the beginning of the period (in shares)		84,000	0
Granted (in shares)	73,588	74,000	85,000
Exercised (in shares)		0	0
Forfeited (in shares)		0	(1,000)
Outstanding at the end of the period (in shares)		158,000	84,000
RSAs
Non-option Shares
Outstanding at the beginning of the period (in shares)		1,351,000	1,141,000
Granted (in shares)		669,000	648,000
Exercised (in shares)		(467,000)	(369,000)
Forfeited (in shares)		(60,000)	(76,000)
Outstanding at the end of the period (in shares)		1,493,000	1,344,000
Shares purchased to cover employee income taxes		160,000	111,000
Treasury stock value		$ 10,600	$ 4,800

BUSINESS COMBINATION - Finite-lived intangible assets acquired as part of business combination (Details) - Alimera Sciences, Inc - USD ($) $ in Thousands		3 Months Ended
	Sep. 16, 2024	Sep. 30, 2024
Business Acquisition [Line Items]
Remaining estimated useful lives		12 years
ILUVIEN
Business Acquisition [Line Items]
Intangible assets acquired	$ 230	$ 230,000
Remaining estimated useful lives	12 years
YUTIQ
Business Acquisition [Line Items]
Intangible assets acquired	$ 170	$ 170,000
Remaining estimated useful lives	12 years

NEW CREDIT AGREEMENT - Maturity of credit facility (Details) - Secured Debt - New Credit Agreement - Line of Credit $ in Thousands	Sep. 30, 2024 USD ($)
Debt Instrument [Line Items]
2024 (remainder of the year)	$ 2,031
2025	10,156
2026	18,281
2027	24,375
2028	24,375
2029	245,782
Long-Term Debt, Total	$ 325,000

REVENUE RECOGNITION AND RELATED ALLOWANCES - Concentration (Details) - Customer Concentration Risk	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Accounts Receivable \| Four Customers
Concentration Risk [Line Items]
Concentration risk, percentage			71.00%
Revenue from Contract with Customer Benchmark \| Customer 1
Concentration Risk [Line Items]
Concentration risk, percentage	20.00%	35.00%	26.00%	33.00%
Revenue from Contract with Customer Benchmark \| Customer 2
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%	12.00%	12.00%	13.00%
Revenue from Contract with Customer Benchmark \| Customer 3
Concentration Risk [Line Items]
Concentration risk, percentage	14.00%	12.00%	12.00%	13.00%
Revenue from Contract with Customer Benchmark \| Customer 4
Concentration Risk [Line Items]
Concentration risk, percentage	17.00%	13.00%	15.00%	10.00%

GOODWILL AND INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of components of intangible assets

The components of definite-lived intangible assets and indefinite-lived intangible assets, other than goodwill, are as follows:


	September 30, 2024						December 31, 2023						Remaining Weighted Average Amortization Period(1)
(in thousands)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Definite-Lived Intangible Assets:
Acquired ANDAs intangible assets	$	210,411	$	(118,804)	$	91,607	$	209,780	$	(100,660)	$	109,120	4.6 years
NDAs and product rights	644,871		(203,143)		441,728		244,871		(184,861)		60,010		11.0 years
Marketing and distribution rights	17,157		(14,992)		2,165		17,157		(14,271)		2,886		2.2 years
Customer relationships	24,900		(10,375)		14,525		24,900		(7,707)		17,193		4.1 years
Total Definite-Lived Intangible Assets	897,339		(347,314)		550,025		496,708		(307,499)		189,209		9.8 years
Indefinite-Lived Intangible Assets:
In process research and development	19,800		—		19,800		19,800		—		19,800		Indefinite
Total Intangible Assets, net	$	917,139	$	(347,314)	$	569,825	$	516,508	$	(307,499)	$	209,009

(1)Weighted average amortization period as of September 30, 2024.

Schedule of expected future amortization expense for definite-lived intangible assets

Expected future amortization expense for definite-lived intangible assets is as follows:


(in thousands)
2024 (remainder of the year)	$	20,647
2025	81,016
2026	67,531
2027	58,564
2028	51,783
2029 and thereafter	270,484
Total	$	550,025

2.25% CONVERTIBLE SENIOR NOTES (Tables)

9 Months Ended

Sep. 30, 2024

Debt Disclosure [Abstract]

Schedule of components of total interest expense related to the notes and term loan


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	2,883	$	7,864	$	16,644	$	22,834
Amortization of deferred financing costs	295		591		1,477		1,773
Capitalized interest	(138)		(142)		(401)		(440)
	$	3,040	$	8,313	$	17,720	$	24,167

Extinguishment of the Credit Facility


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	530	$	—	$	530	$	—
Amortization of deferred financing costs	49		—		49		—
	$	579	$	—	$	579	$	—


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	969	$	—	$	969	$	—
Amortization of finance fees	281		—		281		—
	$	1,250	$	—	$	1,250	$	—

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 144,982	$ 221,121
Restricted cash	35	0
Accounts receivable, net of $91,008 and $97,262 of adjustments for chargebacks and other allowances at September 30, 2024 and December 31, 2023, respectively	196,361	162,079
Inventories	148,042	111,196
Prepaid income taxes	6,104	0
Assets held for sale	0	8,020
Prepaid expenses and other current assets	17,475	17,400
Investment in equity securities	8,298	0
Total Current Assets	521,297	519,816
Non-current Assets
Property and equipment, net	56,704	44,593
Deferred tax assets, net of deferred tax liabilities and valuation allowance	67,661	90,711
Intangible assets, net	569,825	209,009
Goodwill	60,426	28,221
Derivatives and other non-current assets	11,464	12,072
Total Assets	1,287,377	904,422
Current Liabilities
Current debt, net of deferred financing costs	7,152	850
Accounts payable	60,890	36,683
Accrued royalties	23,447	16,276
Accrued compensation and related expenses	29,777	23,786
Accrued government rebates	10,693	12,168
Income taxes payable	0	8,164
Returned goods reserve	37,068	29,678
Current contingent consideration	1,283	12,266
Accrued licensor payment	1,809	0
Accrued expenses and other	17,814	5,606
Total Current Liabilities	189,933	145,477
Non-current Liabilities
Non-current debt, net of deferred financing costs and current component	312,918	284,819
Non-current convertible notes, net of deferred financing costs	305,293	0
Non-current contingent consideration	20,175	11,718
Accrued licensor payment, net of current	21,316	0
Other non-current liabilities	6,944	4,809
Total Liabilities	856,579	446,823
Commitments and Contingencies (Note 15)
Mezzanine Equity
Convertible Preferred Stock, Series A, $0.0001 par value, 1,666,667 shares authorized; 25,000 shares issued and outstanding at September 30, 2024 and December 31, 2023	24,850	24,850
Stockholders’ Equity
Common Stock, $0.0001 par value, 33,333,334 shares authorized; 21,493,799 shares issued and 21,069,863 outstanding at September 30, 2024; 20,730,896 shares issued and 20,466,953 shares outstanding at December 31, 2023	2	2
Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	0	0
Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	0	0
Treasury stock, 423,936 shares of common stock, at cost, at September 30, 2024 and 263,943 shares of common stock, at cost, at December 31, 2023	(20,722)	(10,081)
Additional paid-in capital	510,899	514,103
Accumulated deficit	(89,597)	(80,132)
Accumulated other comprehensive income, net of tax	5,366	8,857
Total Stockholders’ Equity	405,948	432,749
Total Liabilities, Mezzanine Equity, and Stockholders’ Equity	$ 1,287,377	$ 904,422

REVENUE RECOGNITION AND RELATED ALLOWANCES - Timing (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Total net revenues	$ 148,332	$ 131,829	$ 423,802	$ 355,162
Performance obligations satisfied in prior periods			3,300	8,500
Deferred revenue	5,000		5,000		$ 0
Sales of contract manufacture products
Disaggregation of Revenue [Line Items]
Remaining performance obligations	$ 3,800		$ 3,800
Sales of contract manufactured products
Disaggregation of Revenue [Line Items]
Performance obligations period	6 months		6 months
Performance obligations transferred at a point in time
Disaggregation of Revenue [Line Items]
Total net revenues	$ 148,332	131,829	$ 423,802	354,787
Performance obligations transferred over time
Disaggregation of Revenue [Line Items]
Total net revenues	$ 0	$ 0	$ 0	$ 375

FAIR VALUE DISCLOSURES (Tables)

9 Months Ended

Sep. 30, 2024

Fair Value Disclosures [Abstract]

Schedule of changes in fair value, inputs, level 3

The following table presents the changes in the CVR balances classified as Level 3 for the three and nine months ended September 30, 2024 and 2023:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Beginning balance	$	—	$	—	$	—	$	—
CVR Agreement	8,700		—		8,700		—
Ending balance	$	8,700	$	—	$	8,700	$	—

The following table presents the changes in contingent consideration balances classified as Level 3 for the three and nine months ended September 30, 2024 and 2023:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Beginning balance	$	11,933	$	37,054	$	23,984	$	35,058
Payment of Gross-Profit earn-out	—		—		(12,500)		—
Change in fair value	825		(2,555)		1,274		(559)
Ending balance	$	12,758	$	34,499	$	12,758	$	34,499

Schedule of recurring Level 3 fair value measurements of contingent consideration

The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs as of September 30, 2024:

Payment Type

Valuation Technique

Unobservable Input

Assumptions

Profit-based milestone payments

Probability-weighted discounted cash flow

Discount rate

12%

Projected fiscal year of payment

2025-2035

Schedule of financial assets and liabilities accounted for at fair value on a recurring basis


(in thousands) Description	Fair Value at September 30, 2024		Level 1		Level 2		Level 3
Assets
Money Market Fund	$	83,304	$	83,304	$	—	$	—
Interest rate swap	$	3,556	$	—	$	3,556	$	—
CG Oncology - Investment in equity securities	$	8,298	$	8,298	$	—	$	—
Liabilities
Contingent consideration, Novitium	$	12,758	$	—	$	—	$	12,758
Contingent Value Rights, Alimera	$	8,700	$	—	$	—	$	8,700
Accrued licensor payment	$	23,125	$	—	$	—	$	23,125


Description	Fair Value at December 31, 2023		Level 1		Level 2		Level 3
Assets
Money Market Fund	$	191,841	$	191,841	$	—	$	—
Interest rate swap	$	6,236	$	—	$	6,236	$	—
Liabilities
Contingent consideration	$	23,984	$	—	$	—	$	23,984

FAIR VALUE DISCLOSURES - CVR fair value level 3 (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Beginning balance	$ 11,933	$ 37,054	$ 23,984	$ 35,058
CVR Agreement	$ 825	$ (2,555)	$ 1,274	$ (559)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Contingent consideration fair value adjustment	Contingent consideration fair value adjustment	Contingent consideration fair value adjustment	Contingent consideration fair value adjustment
Ending balance	$ 12,758	$ 34,499	$ 12,758	$ 34,499
Level 3 \| Contingent Value Rights Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Beginning balance	0	0	0	0
CVR Agreement	$ 8,700	$ 0	$ 8,700	$ 0
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Contingent consideration fair value adjustment	Contingent consideration fair value adjustment	Contingent consideration fair value adjustment	Contingent consideration fair value adjustment
Ending balance	$ 8,700	$ 0	$ 8,700	$ 0

GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024 USD ($) segment	Dec. 31, 2021 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2013 USD ($)	Sep. 16, 2024 USD ($)	Dec. 31, 2023 USD ($)
Goodwill [Line Items]
Number of operating segments \| segment	2
Number of reporting units \| segment	2
Goodwill	$ 60,426					$ 28,221
BioSante Pharmaceuticals
Goodwill [Line Items]
Acquisition of goodwill				$ 1,800
WellSpring
Goodwill [Line Items]
Acquisition of goodwill			$ 1,700
Novitium
Goodwill [Line Items]
Acquisition of goodwill		$ 24,600
Alimera Sciences, Inc
Goodwill [Line Items]
Goodwill					$ 32,202

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

+ Details

BUSINESS COMBINATION - Narrative (Details) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
	Sep. 16, 2024 USD ($) contingentValueRight $ / shares	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Business Acquisition [Line Items]
Selling, general and administrative expenses		$ 79,075	$ 42,007	$ 179,917	$ 117,235
Research and development expense		10,128	$ 11,121	27,935	$ 24,419
Business combination, pro forma information, revenue of acquiree since acquisition date, actual				3,900
Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual				(8,100)
Alimera Sciences, Inc
Business Acquisition [Line Items]
Common Stock, par value (in dollars per share) \| $ / shares	$ 0.01
Cash consideration per share (in dollars per share) \| $ / shares	$ 5.50
Business combination, number of contingent value rights to be received \| contingentValueRight	1
Business combination, milestone payment multiplier	0.25
Repayment of Alimera Debt	$ 78,540
Payment of Alimera transaction costs	20,172
Payment of settlement of acquiree's equity awards	19,300
Cash paid at closing for settlement of equity awards	1,300
Cash settlement for pre-acquisition equity awards	9,535
Selling, general and administrative expenses		8,800		8,800
Research and development expense		1,000		1,000
Fair value of CVRs	8,322
Business combination, contingent value rights	8,700
Payment of Alimera transaction costs				12,200
Alimera Sciences, Inc \| Contingent Value Right
Business Acquisition [Line Items]
Selling, general and administrative expenses		$ 400		$ 400
Alimera Sciences, Inc \| 2026 Milestone Revenue Payment
Business Acquisition [Line Items]
Revenues	140,000
Business combination, divisible revenue	10,000
Alimera Sciences, Inc \| 2026 Milestone Revenue Payment \| Maximum
Business Acquisition [Line Items]
Revenues	151,000
Alimera Sciences, Inc \| 2027 Milestone Revenue Payment
Business Acquisition [Line Items]
Revenues	160,000
Business combination, divisible revenue	15,000
Alimera Sciences, Inc \| 2027 Milestone Revenue Payment \| Maximum
Business Acquisition [Line Items]
Revenues	$ 176,000

NEW CREDIT AGREEMENT

9 Months Ended

Sep. 30, 2024

Debt Disclosure [Abstract]

NEW CREDIT AGREEMENT

TRUIST CREDIT FACILITY

The carrying value of the current and non-current components of the Term Facility as of September 30, 2024 and December 31, 2023 are:


	Current
(in thousands)	September 30, 2024		December 31, 2023
Current borrowing on debt	$	—	$	3,000
Deferred financing costs	—		(2,150)
Current debt, net of deferred financing costs	$	—	$	850


	Non-Current
(in thousands)	September 30, 2024		December 31, 2023
Non-current borrowing on debt	$	—	$	291,000
Deferred financing costs	—		(6,181)
Non-current debt, net of deferred financing costs and current component	$	—	$	284,819


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	2,883	$	7,864	$	16,644	$	22,834
Amortization of deferred financing costs	295		591		1,477		1,773
Capitalized interest	(138)		(142)		(401)		(440)
	$	3,040	$	8,313	$	17,720	$	24,167

Extinguishment of the Credit Facility

New Credit Agreement

The cash interest rate and effective rate under the Term Loan A was approximately 7.95% and 8.37% per annum at September 30, 2024, respectively.

The carrying value of the current and non-current components of the New Credit Facility as of September 30, 2024 and December 31, 2023 are:


	Current
(in thousands)	September 30, 2024		December 31, 2023
Current borrowing on debt	$	8,125	$	—
Deferred financing costs	(973)		—
Current debt, net of deferred financing costs	$	7,152	$	—


	Non-Current
(in thousands)	September 30, 2024		December 31, 2023
Non-current borrowing on debt	$	316,875	$	—
Deferred financing costs	(3,957)		—
Non-current debt, net of deferred financing costs and current component	$	312,918	$	—

The contractual maturity of the Term Loan A is as follows for the period ending:


(in thousands)	New Term Facility
2024 (remainder of the year)	$	2,031
2025	10,156
2026	18,281
2027	24,375
2028	24,375
2029	245,782
Total	$	325,000


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	530	$	—	$	530	$	—
Amortization of deferred financing costs	49		—		49		—
	$	579	$	—	$	579	$	—

2.25% CONVERTIBLE SENIOR NOTES

Offering of Convertible Senior Notes

Conversion Options

Events of Default

As of September 30, 2024, the total estimated fair value (which represents a Level 2 valuation) of the Notes is approximately $334.8 million.


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Contractual coupon	$	969	$	—	$	969	$	—
Amortization of finance fees	281		—		281		—
	$	1,250	$	—	$	1,250	$	—

Capped Call Transactions

- Definition

+ References

+ Details

SEGMENT REPORTING - Revenue (Details) $ in Thousands	3 Months Ended			9 Months Ended
SEGMENT REPORTING - Revenue (Details) $ in Thousands	Sep. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) segment	Sep. 30, 2023 USD ($)
Segment reporting
Number of operating segments \| segment				2
Total net revenues	$ 148,332		$ 131,829	$ 423,802	$ 355,162
Depreciation and amortization	15,748		15,207	45,131	44,597
Selling, general and administrative expenses	79,075		42,007	179,917	117,235
Operating (loss) income	(20,519)		17,948	4,962	40,245
Unrealized gain on investment in equity securities	1,355		0	8,298	0
Interest expense, net	(2,331)		(6,398)	(11,587)	(21,194)
Other expense, net	(2,535)		(39)	(2,655)	(126)
(Loss) Income Before Income Tax (Benefit) Expense	(31,498)		11,511	(8,450)	18,925
Gain on sale of building	0	$ 5,300	0	5,347	0
Loss on extinguishment of debt	7,468		0	7,468	0
Operating Segments \| Generics, Established Brands, and Other
Segment reporting
Total net revenues	91,906		102,095	281,246	284,794
EBITDA	33,588		41,234	110,528	120,070
Operating Segments \| Rare Disease
Segment reporting
Total net revenues	56,426		29,734	142,556	70,368
EBITDA	6,626		4,044	14,826	6,937
Corporate, Non-Segment
Segment reporting
Depreciation and amortization	(15,748)		(15,207)	(45,131)	(44,597)
Selling, general and administrative expenses	(44,985)		(12,123)	(75,261)	(42,165)
Operating (loss) income	(20,519)		17,948	4,962	40,245
Unrealized gain on investment in equity securities	1,355		0	8,298	0
Interest expense, net	(2,331)		(6,398)	(11,587)	(21,194)
Other expense, net	$ (10,003)		$ (39)	$ (10,123)	$ (126)

RELATED PARTY TRANSACTIONS (Details)						3 Months Ended		9 Months Ended
RELATED PARTY TRANSACTIONS (Details)	Feb. 29, 2024 USD ($)	Feb. 22, 2024 USD ($)	Dec. 12, 2023 USD ($)	Nov. 19, 2021 USD ($) $ / shares shares	Mar. 08, 2021 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) founder	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) founder	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Related Party Transaction [Line Items]
Number of executive founders \| founder						2		2
Outstanding balances						$ 60,890,000		$ 60,890,000		$ 36,683,000
Payments on contingent consideration								12,500,000	$ 0
Novitium
Related Party Transaction [Line Items]
Payments on contingent consideration		$ 12,500,000	$ 12,500,000
Convertible Preferred Stock \| PIPE Shares
Related Party Transaction [Line Items]
Temporary stock issued (in shares) \| shares				25,000	25,000
Temporary stock issued (in dollars per share) \| $ / shares				$ 1,000	$ 1,000
Temporary stock issued, value				$ 25,000,000.0	$ 25,000,000.0
Related Party
Related Party Transaction [Line Items]
Payments to related party						5,448,000	$ 3,802,000	8,843,000	9,286,000
Related Party \| Mr. Shanmugam and Esjay \| Novitium
Related Party Transaction [Line Items]
Payments on contingent consideration	$ 6,700,000		6,700,000
Related Party \| Chali Properties LLC \| Novitium
Related Party Transaction [Line Items]
Payments on contingent consideration	$ 1,900,000		$ 1,900,000
Related Party \| Scitus Pharma Services
Related Party Transaction [Line Items]
Payments to related party						1,155,000	1,322,000	2,236,000	3,227,000
Outstanding balances						400,000		400,000
Related Party \| SS Pharma LLC
Related Party Transaction [Line Items]
Payments to related party						0	2,480,000	1,245,000	6,059,000
Outstanding balances						0		0
Related Party \| SThree Chemicals Pvt Ltd
Related Party Transaction [Line Items]
Payments to related party						4,214,000	0	5,283,000	0
Outstanding balances						1,600,000		1,600,000
Related Party \| Esjay Pharma LLC
Related Party Transaction [Line Items]
Payments to related party						79,000	$ 0	79,000	$ 0
Outstanding balances						$ 14,000		$ 14,000

TRUIST CREDIT FACILITY - Credit facility (Details) - USD ($) $ in Thousands			3 Months Ended		9 Months Ended
	Aug. 13, 2024	Nov. 19, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Debt Instrument [Line Items]
Repayments of long-term lines of credit					$ 292,500	$ 0
Term Facility
Debt Instrument [Line Items]
Total			$ 3,040	$ 8,313	17,720	$ 24,167
Line of Credit \| The Credit Facility
Debt Instrument [Line Items]
Deferred debt issuance costs			14,000		14,000
Convertible Debt \| Convertible Senior Notes due 2029
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	2.25%
Credit Facility - 2021 \| Term Facility
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 300,000
Repayments of long-term lines of credit	$ 294,000
Long-term debt, gross	292,500
Total	1,200
Debt Instrument, Legal Fees	$ 300
Write-off unamortized deferred financing			$ 7,500		$ 7,500
Credit Facility - 2021 \| Line of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 40,000
Commitment fee (as a percent)		0.50%

NEW CREDIT AGREEMENT - Interest (Details) - Secured Debt - New Credit Agreement - Line of Credit - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Debt Instrument [Line Items]
Contractual coupon	$ 530	$ 0	$ 530	$ 0
Amortization of deferred financing costs	49	0	49	0
Total	$ 579	$ 0	$ 579	$ 0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net (Loss) Income	$ (24,166)	$ 9,940	$ (8,246)	$ 17,624

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

RELATED PARTY TRANSACTIONS (Tables)

9 Months Ended

Sep. 30, 2024

Schedule of related party transactions

A summary of payments to related parties is presented below:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Scitus Pharma Services	$	1,155	$	1,322	$	2,236	$	3,227
SS Pharma LLC	—		2,480		1,245		6,059
SThree Chemicals Pvt Ltd	4,214		—		5,283		—
Esjay Pharma LLC	79		—		79		—
	$	5,448	$	3,802	$	8,843	$	9,286

SEGMENT REPORTING (Tables)

9 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

Schedule of financial information by reportable segments

Financial information by reportable segment is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Net Revenues
Generics, Established Brands, and Other	$	91,906	$	102,095	$	281,246	$	284,794
Rare Disease	56,426		29,734		142,556		70,368
Total net revenues	$	148,332	$	131,829	$	423,802	$	355,162

Segment earnings before interest, taxes, depreciation and amortization (“EBITDA”) and reconciliation to income before income taxes
Generics, Established Brands, and Other	$	33,588	$	41,234	$	110,528	$	120,070
Rare Disease	6,626		4,044		14,826		6,937
Depreciation and amortization	(15,748)		(15,207)		(45,131)		(44,597)
Corporate and other unallocated expenses(1)	(44,985)		(12,123)		(75,261)		(42,165)
Total operating (loss) income	(20,519)		17,948		4,962		40,245

Unrealized gain on investment in equity securities	1,355		—		8,298		—
Interest expense, net	(2,331)		(6,398)		(11,587)		(21,194)
Other expense, net (2)	(10,003)		(39)		(10,123)		(126)
(Loss) Income Before Income Tax (Benefit) Expense	$	(31,498)	$	11,511	$	(8,450)	$	18,925

______________________________________________

(1)Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, transaction and integration expenses related to the acquisition of Alimera, severance and equity payouts, and are included in selling, general, and administrative expenses in our unaudited interim consolidated statement of operations. This amount also includes the gain on the sale of the Oakville, Ontario site of approximately $5.3 million, which occurred in the first quarter of 2024.

(2)The loss on extinguishment of approximately $7.5 million, which occurred in the third quarter of 2024 is included in Other expense, net above. Refer to Note 4 “Restructuring Canada Operations” to the Notes to Condensed Consolidated Financial Statements for further information.

Schedule of revenue by geographic operations

The following table depicts the Company’s revenue by geographic operations during the following periods:


(in thousands)	Three Months Ended September 30,				Nine Months Ended September 30,
Location of Operations	2024		2023		2024		2023
United States	$	147,116	$	131,829	$	422,586	$	354,597
International	1,216		—		1,216		565
Total Revenue	$	148,332	$	131,829	$	423,802	$	355,162

Schedule of property, plant and equipment, net by geographic location

The Company’s property, plant and equipment are as follows:


(in thousands)	September 30, 2024		December 31, 2023
United States	$	54,637	$	43,163
International	2,067		1,430
Total property and equipment, net	$	56,704	$	44,593

BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS	BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS Overview ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, “ANI,” the “Company,” “we,” “us,” or “our”) is a diversified bio-pharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. On September 16, 2024, the Company completed its previously announced acquisition of Alimera Sciences, Inc., a Delaware corporation (“Alimera”) pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024, by and among the Company, Alimera and ANIP Merger Sub INC., a Delaware corporation and wholly-owned subsidiary of the Company. Pursuant to the Merger Agreement, Merger Sub merged with and into Alimera, with Alimera surviving the merger as a wholly-owned subsidiary of the Company. In connection with the acquisition, the Company added two new products, ILUVIEN® and YUTIQ®, both of which are indicated for the treatment of chronic retinal diseases. See Note 3 “Business Combination” to the Notes to Condensed Consolidated Financial Statements for further information on the acquisition. The Company’s three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. The Company ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. This action was part of ongoing initiatives to capture operational synergies following the acquisition of Novitium Pharma LLC (“Novitium”) in November 2021. The Company has fully completed the transition of the products manufactured or packaged in Oakville to one of the three U.S. based manufacturing sites. In February 2024, the Company entered into an agreement for the sale of the Oakville site, for a price of $19.2 million Canadian Dollars, or approximately $14.2 million, based on the exchange rate at closing of such transaction. The sale closed on March 28, 2024 (see Note 4 “Restructuring Canada Operations” to the Notes to Condensed Consolidated Financial Statements). The Company’s operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, and possible fluctuations in financial results. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company’s financial position, results of operations, comprehensive (loss) income, and cash flows. The consolidated balance sheet at December 31, 2023 has been derived from audited financial statements as of that date. The unaudited interim condensed consolidated statements of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the U.S. Securities and Exchange Commission (the “SEC”). Therefore, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto previously distributed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”), as filed with the SEC. Principles of Consolidation The unaudited interim condensed consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Foreign Currency The Company currently has subsidiaries located in India, Ireland, Germany, and the United Kingdom. The India-based subsidiary generally conducts its transactions in Indian upees, which is also its functional currency. The Ireland and Germany locations generally conduct their transactions in Euros, which is also their functional currency. The United Kingdom subsidiary conducts its transactions in Euros and British Pounds, and their functional currency is Euros. The Company has ceased operations at its subsidiary in Oakville, Ontario, Canada as of March 31, 2023. The Canada-based subsidiary conducted its transactions in U.S. dollars and Canadian dollars, but its functional currency was the U.S. dollar. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net (loss) income. The gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the three and nine months ended September 30, 2024 and 2023. Unless otherwise noted, all references to “$” or “dollar” refer to the U.S. dollar. The Company’s asset and liability accounts are translated using the current exchange rate as of the balance sheet date, except for shareholders’ equity accounts, which are translated using historical rates. Net revenues and expense accounts are translated using an average exchange rate over the period ended on the balance sheet date. Adjustments resulting from the translation of the financial statements of the Company’s foreign subsidiaries into U.S. dollars are accumulated as a separate component of shareholders’ equity within accumulated other comprehensive (loss) income, net of tax. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the condensed consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, income tax provision or benefit, deferred taxes and valuation allowance, stock-based compensation, revenue recognition, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration and contingent value rights in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness. Business Combination and Goodwill The Company accounted for its acquisition of Alimera using the acquisition method of accounting prescribed by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 805, Business Combinations, whereby the results of operations, including the revenues and earnings of Alimera, are included in the financial statements from the date of acquisition. Assets acquired and liabilities assumed as of the date of acquisition are recognized at their fair values based on widely accepted valuation techniques in accordance with ASC 820, Fair Value Measurements. Goodwill is recognized for the excess of the consideration transferred over the net fair values of assets acquired and liabilities assumed. Management’s assessment of qualitative factors affecting goodwill for each acquisition includes estimates of market share at the date of purchase, ability to grow in the market, synergy with existing Company operations and the payor profile in the markets. The fair value assigned to the intangible assets was determined using the income approach, specifically the multi-period excess earnings methodology. The process for estimating fair values requires the use of significant estimates, assumptions and judgments, including determining the timing and estimates of future cash flows and developing appropriate discount rates. The estimates of fair value are based upon assumptions believed to be reasonable using the best information available. These assumptions are inherently uncertain and unpredictable and, as a result, actual results may differ materially from estimates. ASC 805, Business Combinations, establishes a measurement period to provide the Company with a reasonable amount of time to obtain the information necessary to identify and measure various items in a business combination and cannot extend beyond one year from the acquisition date. Measurement period adjustments are recognized in the reporting period in which the adjustments are determined and calculated as if the accounting had been completed as of acquisition date. The Company expects to complete the final fair value determination of the assets acquired and liabilities assumed as soon as practicable within the measurement period, but not to exceed one year from the acquisition date. Investment in Equity Securities The Company accounts for its investment in equity securities with a readily determinable fair value in accordance with the guidance in ASC 321, Investments – Equity Securities. The Company presents unrealized gains and losses related to the equity securities, within Unrealized gain on investment in equity securities in its unaudited condensed consolidated statements of operations. Fair values are obtained from quoted prices on the NASDAQ Stock Market, Inc. (“NASDAQ”). Assets Held-for-Sale The Company classifies assets held-for-sale if all held-for-sale criteria is met pursuant to ASC 360-10, Property, Plant and Equipment. Criteria include management commitment to sell the disposal group in its present condition and the sale being deemed probable of being completed within one year. Assets classified as held-for-sale are not depreciated and are measured at the lower of their carrying amount or fair value less cost to sell. The Company assesses the fair value of a disposal group, less any costs to sell, each reporting period it remains classified as held-for-sale and reports any subsequent changes as an adjustment to the carrying value of the disposal group, as long as the new carrying value does not exceed the initial carrying value of the disposal group. The Company determined that the Oakville, Ontario, Canada property met the held-for-sale criteria. As of December 31, 2023, approximately $8.0 million of assets held for sale were recorded on the consolidated balance sheets. The Oakville, Ontario property was sold on March 28, 2024 (see Note 4 “Restructuring Canada Operations” to the Notes to Condensed Consolidated Financial Statements). Recent Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures related to significant segment expenses. The guidance in this ASU is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. While this ASU will increase and enhance disclosures, it will not have a material impact on the Company's consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes guidance to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. These amendments are effective for all public entities for fiscal periods beginning after December 15, 2024, with early adoption permitted. These amendments apply on a prospective basis, but entities have an option to apply it retrospectively for all periods presented. Recent Securities and Exchange Commission Final Rules Issued but Not Yet Effective On March 6, 2024, the SEC adopted new rules that will require registrants to disclose certain climate-related information in their annual reports. The final rule requires disclosure of, among other things: material climate-related risks and their material impacts; activities to mitigate or adapt to such risks; information about a registrant’s board of directors’ oversight of climate-related risks and management’s role in managing material climate-related risks; and information on any climate-related targets or goals that are material to the registrant’s business, results of operations, or financial condition. In addition, certain disclosures related to severe weather events and other natural conditions will be required in a registrant’s audited financial statements. The required information about climate-related risks will also include disclosure of a registrant’s greenhouse gas emissions. The Company will be subject to the applicable requirements of the final rule in our annual reports for fiscal years beginning on January 1, 2025. In April 2024, the SEC voluntarily stayed the rules pending judicial review. The Company is currently evaluating the potential impact of these rules on its consolidated financial statements and related disclosures.

STOCK-BASED COMPENSATION - Expense (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	May 21, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
2016 Employee Stock Purchase Plan
Share-based Compensation
Stock-based compensation shares available		100,000		100,000
Discount from market price (as a percent)				15.00%
Allocated share-based compensation expense		$ 195	$ 139	$ 555	$ 330
2016 Employee Stock Purchase Plan \| Selling, general, and administrative
Share-based Compensation
Allocated share-based compensation expense		142	109	418	251
2016 Employee Stock Purchase Plan \| Research and development
Share-based Compensation
Allocated share-based compensation expense		18	14	42	33
2016 Employee Stock Purchase Plan \| Cost of sales
Share-based Compensation
Allocated share-based compensation expense		$ 35	16	$ 95	46
2022 Plan
Share-based Compensation
Stock-based compensation shares available		1,900,000		1,900,000
Allocated share-based compensation expense		$ 7,288	5,305	$ 21,728	14,701
Stock-based compensation additional shares authorized	1,610,000
2022 Plan \| Selling, general, and administrative
Share-based Compensation
Allocated share-based compensation expense		6,582	4,914	19,883	13,588
2022 Plan \| Research and development
Share-based Compensation
Allocated share-based compensation expense		423	225	1,029	638
2022 Plan \| Cost of sales
Share-based Compensation
Allocated share-based compensation expense		$ 283	$ 166	$ 816	$ 475

DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Aug. 30, 2024	Dec. 31, 2023	Nov. 21, 2021
Derivative [Line Items]
Fair value interest rate derivative assets	$ 3,556		$ 3,556			$ 6,236
Accumulated other comprehensive (loss) income, net of tax	5,366		5,366			$ 8,857
Derivative unrealized gain recorded in OCI	(2,862)	$ 388	(3,282)	$ 1,857
Interest expense	2,331	6,398	11,587	21,194
Interest Rate Swap
Derivative [Line Items]
Derivative liability, notional amount	139,400		139,400				$ 168,600
Debt effective interest rate (as a percent)					2.313%
Fair value interest rate derivative assets	3,600		3,600
Accumulated other comprehensive (loss) income, net of tax	5,600		5,600
Derivative unrealized gain recorded in OCI	2,800		3,300
Interest expense	1,700	700	4,900	1,800
Reclassifications out of accumulated other comprehensive (loss) income	$ 200	$ 700	$ 600	$ 2,100

- Definition

Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.

+ References + Details

- Definition

Nominal or face amount used to calculate payments on the derivative liability.

+ References + Details

STOCK-BASED COMPENSATION - Option activity (Details) - Options - shares shares in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Option Shares
Outstanding at the beginning of the period (in shares)	689	907
Granted (in shares)	0	3
Exercised (in shares)	(57)	(151)
Forfeited (in shares)	(1)	(28)
Outstanding at the end of the period (in shares)	631	731

GOODWILL AND INTANGIBLE ASSETS - Amortization (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
2024 (remainder of the year)	$ 20,647
2025	81,016
2026	67,531
2027	58,564
2028	51,783
2029 and thereafter	270,484
Total	$ 550,025	$ 189,209

SEGMENT REPORTING - Geographic (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Segment reporting
Total net revenues	$ 148,332	$ 131,829	$ 423,802	$ 355,162
Assets held for sale	0		0		$ 8,020
Total property and equipment, net	56,704		56,704		44,593
United States
Segment reporting
Total net revenues	147,116	131,829	422,586	354,597
Total property and equipment, net	54,637		54,637		43,163
International
Segment reporting
Total net revenues	1,216	$ 0	1,216	$ 565
Total property and equipment, net	$ 2,067		$ 2,067		1,430
CANADA
Segment reporting
Assets held for sale					$ 8,000

- Definition

+ References

+ Details

FAIR VALUE DISCLOSURES - Hierarchy (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money Market Fund	$ 83,304	$ 191,841
Interest rate swap	3,556	6,236
Royalties fair value	8,298
Contingent consideration, Novitium	12,800	24,000
Accrued licensor payment	23,125
Level 1
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money Market Fund	83,304	191,841
Interest rate swap	0	0
Royalties fair value	8,298
Accrued licensor payment	0
Level 2
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money Market Fund	0	0
Interest rate swap	3,556	6,236
Royalties fair value	0
Accrued licensor payment	0
Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money Market Fund	0	0
Interest rate swap	0	0
Royalties fair value	0
Accrued licensor payment	23,125
Novitium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, Novitium	12,758	23,984
Novitium \| Level 1
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, Novitium	0	0
Novitium \| Level 2
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, Novitium	0	0
Novitium \| Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, Novitium	12,758	$ 23,984
Alimera Sciences, Inc
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, Novitium	8,700
Alimera Sciences, Inc \| Level 1
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, Novitium	0
Alimera Sciences, Inc \| Level 2
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, Novitium	0
Alimera Sciences, Inc \| Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, Novitium	$ 8,700

SEGMENT REPORTING

9 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

SEGMENT REPORTING

An operating segment is defined as a component of an entity that engages in business activities from which it may recognize revenues and incur expense, its operating results are regularly reviewed by the entity’s chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance, and its discrete financial information is available. The CODM for the Company is the Chief Executive Officer. The Company is organized into two operating segments as follows:

•Generics, Established Brands, and Other – Consists of operations related to the development, manufacturing, and marketing of generic and established brand pharmaceuticals, including those sold through traditional channels, contract manufactured products, product development services, royalties, and other.

•Rare Disease – Consists of operations related to the development, manufacturing and marketing of pharmaceuticals used in the treatment of patients with rare conditions. The rare disease segment currently consists of operations related to Cortrophin Gel, and the products acquired as part of the Merger with Alimera, ILUVIEN and YUTIQ, as of and from September 16, 2024 through the end of the quarter.

The CODM evaluates the two operating segments based on revenues and earnings before interest, income taxes, depreciation, and amortization (“EBITDA”), exclusive of corporate expenses and other expenses not directly allocated or attributable to an operating segment. These expenses include, but are not limited to, certain management, legal, accounting, human resources, insurance, and information technology expenses, and transaction and integration expenses related to the acquisition of Alimera.

The Company does not manage assets of the Company by operating segment, and our CODM does not review asset information by operating segment. Accordingly, the Company does not present total assets by operating segment.

Financial information by reportable segment is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Net Revenues
Generics, Established Brands, and Other	$	91,906	$	102,095	$	281,246	$	284,794
Rare Disease	56,426		29,734		142,556		70,368
Total net revenues	$	148,332	$	131,829	$	423,802	$	355,162

Segment earnings before interest, taxes, depreciation and amortization (“EBITDA”) and reconciliation to income before income taxes
Generics, Established Brands, and Other	$	33,588	$	41,234	$	110,528	$	120,070
Rare Disease	6,626		4,044		14,826		6,937
Depreciation and amortization	(15,748)		(15,207)		(45,131)		(44,597)
Corporate and other unallocated expenses(1)	(44,985)		(12,123)		(75,261)		(42,165)
Total operating (loss) income	(20,519)		17,948		4,962		40,245

Unrealized gain on investment in equity securities	1,355		—		8,298		—
Interest expense, net	(2,331)		(6,398)		(11,587)		(21,194)
Other expense, net (2)	(10,003)		(39)		(10,123)		(126)
(Loss) Income Before Income Tax (Benefit) Expense	$	(31,498)	$	11,511	$	(8,450)	$	18,925

______________________________________________

Geographic Information

The following depicts the Company's total revenue according to geographic location. The Company has ceased operations at the Oakville, Ontario, Canada location as of March 31, 2023. The revenue from Alimera is also included in the three and nine months ended September 30, 2024 in the table below. The majority of the assets of the Company are located in the United States.

The following table depicts the Company’s revenue by geographic operations during the following periods:


(in thousands)	Three Months Ended September 30,				Nine Months Ended September 30,
Location of Operations	2024		2023		2024		2023
United States	$	147,116	$	131,829	$	422,586	$	354,597
International	1,216		—		1,216		565
Total Revenue	$	148,332	$	131,829	$	423,802	$	355,162

The following table depicts the Company’s property, plant and equipment, net according to geographic location, which excludes the land and building at the Company’s Canada facility, which was classified as held for sale as of December 31, 2023. These assets had a carrying value of approximately $8.0 million. The land and building at the Canada facility was sold on March 28, 2024, refer to Note 4 “Restructuring Canada Operations” to the Notes to Condensed Consolidated Financial Statements. The table below includes Alimera property, plant and equipment, net, as of September 30, 2024. The Company’s property, plant and equipment are as follows:


(in thousands)	September 30, 2024		December 31, 2023
United States	$	54,637	$	43,163
International	2,067		1,430
Total property and equipment, net	$	56,704	$	44,593

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

STOCK-BASED COMPENSATION - Information (Details)	9 Months Ended
STOCK-BASED COMPENSATION - Information (Details)	Sep. 30, 2024 installment
Options
Share-based Compensation
Number of annual installments	4
Options \| Employees and Consultants
Share-based Compensation
Vesting period	4 years
Award expiration period	10 years
Options \| Non Employee Director
Share-based Compensation
Award expiration period	10 years
Options \| Non Employee Director \| Minimum
Share-based Compensation
Vesting period	1 year
Options \| Non Employee Director \| Maximum
Share-based Compensation
Vesting period	4 years
RSAs \| Employees and Consultants
Share-based Compensation
Vesting period	4 years
RSAs \| Non Employee Director
Share-based Compensation
Vesting period	1 year

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Valuation allowance	$ 400		$ 400
Expense (benefit) for income taxes	$ (7,332)	$ 1,571	$ (204)	$ 1,301
Effective income tax rate (as a percent)	(23.30%)	13.60%	(2.40%)	6.90%

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

MEZZANINE AND STOCKHOLDERS' EQUITY	9 Months Ended
MEZZANINE AND STOCKHOLDERS' EQUITY	Sep. 30, 2024
Stockholders' Equity Note [Abstract]
MEZZANINE AND STOCKHOLDERS' EQUITY	MEZZANINE AND STOCKHOLDERS’ EQUITY Stockholders’ Equity Authorized shares The Company is authorized to issue up to 33.3 million shares of common stock with a par value of $0.0001 per share, 0.8 million shares of class C special stock with a par value of $0.0001 per share, and 1.7 million shares of undesignated preferred stock with a par value of $0.0001 per share at September 30, 2024. There were 21.5 million and 21.1 million shares of common stock issued and outstanding as of September 30, 2024, respectively, and 20.7 million and 20.5 million shares of common stock issued and outstanding as of December 31, 2023, respectively. Class C Special Stock There were 11 thousand shares of class C special stock issued and outstanding as of September 30, 2024 and December 31, 2023. Each share of class C special stock entitles its holder to one vote per share. Each share of class C special stock is exchangeable, at the option of the holder, for one share of common stock, at an exchange price of $90.00 per share, subject to adjustment upon certain capitalization events. Holders of class C special stock are not entitled to receive dividends or to participate in the distribution of our assets upon liquidation, dissolution, or winding-up the Company. The holders of class C special stock have no cumulative voting, preemptive, subscription, redemption, or sinking fund rights. Mezzanine Equity PIPE Shares Concurrently with the execution of the Novitium Merger Agreement, and as financing for a portion of the acquisition, on March 8, 2021, the Company entered into an Equity Commitment and Investment Agreement with Ampersand 2020 Limited Partnership (the “PIPE Investor”), pursuant to which the PIPE Investor purchased 25,000 shares of Series A Convertible Preferred Stock (the “PIPE Shares”), for a purchase price of $1,000 per share and an aggregate purchase price of $25.0 million on November 19, 2021. The PIPE Shares are classified as mezzanine equity because the shares are mandatorily redeemable for cash upon a change in control, an event that is not solely within the Company’s control. The PIPE Shares accrue dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind, and will also participate, on a pro-rata basis, in any dividends that may be declared with respect to our common stock. The PIPE Shares are convertible into common shares at the conversion price of $41.47 (i) beginning two years after their issuance date, at the election of ANI (in which case the PIPE Investor must convert all of the PIPE Shares), if the volume-weighted average price of the common stock for any 20 trading days out of 30 consecutive trading days exceeds 170% of the conversion price, and (ii) at any time after issuance, at the election of the PIPE Investor. As of September 30, 2024, the PIPE shares are currently convertible into a maximum of 602,901 shares of common stock. In case of a liquidation event, the holder of the PIPE Shares will be entitled to receive, in preference to holders of the Company’s common stock, the greater of (i) the PIPE Shares’ purchase price plus any accrued and unpaid dividends thereon and (ii) the amount the holder of the PIPE Shares would have received in the liquidation event if it had converted its PIPE Shares into common stock. The PIPE Shares will have voting rights, voting as one series with the holders of common stock, on as-converted basis, and will have separate voting rights on any (i) amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “Certificate”) that adversely amends and relates solely to the terms of the PIPE Shares and (ii) issuance of additional Series A convertible preferred stock. In case of a change of control, the PIPE Shares will be redeemed at the greater of (i) the PIPE Shares’ purchase price plus any accrued and unpaid dividends thereon and (ii) the change of control transaction consideration that the PIPE Investor would have received if it had converted into shares of common stock. There were 25,000 shares of Series A convertible preferred stock outstanding as of September 30, 2024.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)

9 Months Ended

Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue and revenue recognized


	Three Months Ended September 30,				Nine Months Ended September 30,
Products and Services (in thousands)	2024		2023		2024		2023
Rare Disease
Sales of Cortrophin Gel	$	52,555	$	29,734	$	138,685	$	70,368
Sales of ILUVIEN and YUTIQ	3,871		—		3,871		—
Total sales of rare disease pharmaceutical products	$	56,426	$	29,734	$	142,556	$	70,368
Generics, Established Brands, and Other
Sales of generic pharmaceutical products	$	78,223	$	70,593	$	222,404	$	197,623
Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services	13,683		31,502		58,842		87,171
Total sales of generic and established brand pharmaceutical products, royalties, and other pharmaceuticals services	91,906		102,095		281,246		284,794
Total net revenues	$	148,332	$	131,829	$	423,802	$	355,162


	Three Months Ended September 30,				Nine Months Ended September 30,
Timing of Revenue Recognition (in thousands)	2024		2023		2024		2023
Performance obligations transferred at a point in time	$	148,332	$	131,829	$	423,802	$	354,787
Performance obligations transferred over time	—		—		—		375
Total	$	148,332	$	131,829	$	423,802	$	355,162

Schedule of accruals and allowances

The following table summarizes activity in the condensed consolidated balance sheets for accruals and allowances for the nine months ended September 30, 2024 and 2023, respectively:


	Accruals for Chargebacks, Returns, and Other Allowances
(in thousands)	Chargebacks		Government Rebates		Returns		Administrative Fees and Other Rebates		Prompt Payment Discounts
Balance at December 31, 2022	$	148,562	$	10,872	$	33,399	$	9,442	$	6,488
Accruals/Adjustments	437,671		16,998		13,048		40,815		17,024
Credits Taken Against Reserve	(501,841)		(16,947)		(15,009)		(39,316)		(18,366)
Balance at September 30, 2023 (1)	$	84,392	$	10,923	$	31,438	$	10,941	$	5,146

Balance at December 31, 2023	$	84,208	$	12,168	$	29,678	$	11,412	$	4,865
Impact of Alimera acquisition	95		—		3,095		671		—
Accruals/Adjustments	403,201		19,757		28,737		44,622		17,159
Credits Taken Against Reserve	(410,508)		(21,232)		(24,442)		(43,486)		(17,218)
Balance at September 30, 2024 (1)	$	76,996	$	10,693	$	37,068	$	13,219	$	4,806

______________________________________________

Schedule of customer concentration

The four customers represent the total percentage of net revenues as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Customer 1	20	%	35	%	26	%	33	%
Customer 2	10	%	12	%	12	%	13	%
Customer 3	14	%	12	%	12	%	13	%
Customer 4	17	%	13	%	15	%	10	%

Condensed Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Net (Loss) Income	$ (24,166)	$ 9,940	$ (8,246)	$ 17,624
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustment	(100)	(38)	(209)	52
(Loss) Gain on interest rate swap	(2,862)	388	(3,282)	1,857
Total other comprehensive (loss) income, net of tax	(2,962)	350	(3,491)	1,909
Total comprehensive (loss) income, net of tax	$ (27,128)	$ 10,290	$ (11,737)	$ 19,533

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-4

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482739/220-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

+ Details

BUSINESS COMBINATION

9 Months Ended

Sep. 30, 2024

Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]

BUSINESS COMBINATION

Summary

On September 16, 2024 (the “Closing Date”), the Company completed the previously announced acquisition (the “Acquisition” or the “Merger”) of Alimera Sciences, Inc., a Delaware corporation (“Alimera”) pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the “Merger Agreement”), by and among the Company, Alimera and ANIP Merger Sub INC., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”). Pursuant to the Merger Agreement, Merger Sub merged with and into Alimera, with Alimera surviving the Merger as a wholly owned subsidiary of the Company.

At the effective time of the Merger, each share of common stock, par value $0.01 per share, of Alimera (the “Alimera Common Stock”) outstanding, including each Alimera RSA (as defined below), but excluding any treasury shares or shares owned by the Company, Merger Subs or any other subsidiary of the Company or Alimera, was canceled and ceased to exist and was converted into the right to receive (i) $5.50 in cash (“Closing Cash Consideration”), and (ii) one contingent value right (a “CVR”), which represents the right to receive the milestone payments (as defined below) subject to the terms and conditions set forth in the CVR Agreement entered into on September 16, 2024 ( collectively, the “Merger Consideration”).

Each CVR entitles the holder to receive milestone payments for 2026 and 2027. The milestone payments for each CVR equals the product (rounded to the nearest 1/100 of $0.01) of $0.25 multiplied by a fraction (which in no case will exceed one), and (i) for 2026, equals the amount, if any, by which the 2026 Net Revenue (as defined in the Merger Agreement) exceeds $140.0 million, divided by $10.0 million (subject to adjustment for the exercise price of eligible options). If the Net Revenue for 2026 were $151.0 million, then the fraction would exceed one and would count as one, multiplied by $0.25, and the Milestone Payment for 2026 would be $0.25. For the avoidance of doubt, in no circumstance will more than $0.25 per CVR be payable in respect of the Net Revenue for 2026.

For 2027, the milestone payments for each CVR equals the amount, if any, by which the 2027 Net Revenue exceeds $160.0 million, divided by $15.0 million (subject to adjustment for the exercise price of applicable Alimera Options). If the Net Revenue for 2027 were $176.0 million, then the fraction would exceed one and would count as one, multiplied by $0.25, and the Milestone Payment for 2027 would be $0.25. For the avoidance of doubt, in no circumstance will more than $0.25 per CVR be payable in respect of the Net Revenue for 2027.

In addition to the amounts payable to the holders thereof in connection with the Closing, all of the outstanding awards of restricted stock with respect to shares of Alimera Common Stock (each, an “Alimera RSA”), each Alimera Performance Stock Unit (“Alimera PSU”), each Alimera Restricted Stock Unit (“Alimera RSU”) and each Alimera Warrant that were outstanding immediately prior to the Effective Time were automatically canceled and converted into the right to receive one (1) CVR per share of Alimera Common Stock then underlying the applicable instrument.

Each stock option previously granted by Alimera to purchase Alimera Common Stock (each, an “Alimera Option”) that was outstanding and unexercised as of the Effective Time and which had a per share exercise price that was less than the Closing Cash Consideration was, in addition to the amounts payable to the holders thereof in connection with the Closing, automatically canceled and converted into the right to receive one (1) CVR per share of Alimera Common Stock then underlying such Alimera Option. No other Alimera Options were cancelled and converted into the right to receive a CVR, provided that each Alimera Option with a per share exercise price greater than or equal to the Closing Cash Consideration but less than the Total Consideration (as defined in the Merger Agreement) may receive a payment in connection with the payout of the CVRs (if any).

This acquisition was accounted for as a business combination. Purchase consideration consisted of the following:


(In thousands, except share price and exchange ratio)	Purchase Consideration
Alimera common shares outstanding	53,971
Alimera warrants outstanding after exercise	989
Alimera common shares and warrants outstanding	54,960
Cash consideration per share	$	5.50
Cash consideration for Alimera Common Stock	$	302,280

Repayment of Alimera Debt	78,540
Payment of Alimera transaction costs	20,172
Cash settlement for pre-acquisition equity awards	9,535
Fair value of CVRs	8,322
Total Merger Consideration	$	418,849

The cash payment was funded through the New Credit Facility, see Note 6 “New Credit Agreement” to the Notes to Condensed Consolidated Financial Statements for further details.

As part of the purchase consideration the Company paid approximately $78.5 million for the repayment of the outstanding term loan Alimera had with SLR Investment Corp., including interest payable, prepayment and end of term fees. Furthermore, the Company repaid $20.2 million of transaction costs incurred by Alimera.

In accordance with the terms of the Merger Agreement, the Company settled all outstanding equity awards held by Alimera employees, for a total cash amount of $19.3 million, of which, $1.3 million was paid in cash at the close of the Merger. Of the $19.3 million, $9.5 million was determined to be related to the pre-Merger services provided and as a result was allocated to the purchase consideration transferred. The remaining amounts were attributed to the post-Merger period and deemed to be for the benefit of ANI the Company. As a result, $8.8 million was recognized as selling, general, and administrative and $1.0 million as research and development expense, respectively, for the three and nine months ended September 30, 2024.

The CVRs represent a form of contingent consideration and are included as part of the purchase consideration transferred. The CVRs represent the right to future cash payments for the former Alimera shareholders based on certain 2026 and 2027 revenue targets. Management determined the contingent consideration to be liability classified and will measure the liability at fair value each reporting period. The fair value of the CVRs have been estimated using a monte carlo simulation under an option pricing framework, $8.3 million of the total $8.7 million was related to the pre-combination period and recognized as consideration transferred. The remaining $0.4 million of the fair value of the CVR was allocated to post-merger period and recognized as selling, general, and administrative for the three and nine months ended September 30, 2024.

The preliminary allocation of the fair value of the Alimera acquisition is shown in the table below. The allocation of the fair value will be finalized when the valuation is completed, and the differences will be trued up for the final allocated amounts.


	Fair Value
Cash and cash equivalents	$	9,247
Accounts receivable	38,605
Prepaid expenses and other assets	2,618
Inventories	19,457
Property and equipment	3,086
Intangible assets	400,000
Deferred tax asset, net of deferred tax liabilities and valuation allowance	198
Derivative and other non-current assets	1,224
Total assets	$	474,435

Accounts payable	$	8,001
Accrued expenses and other	11,396
Returned goods reserve	3,095
Current accrued licensor payment	3,684
Accrued licensor payment, net of current	21,316
Deferred tax liability	37,932
Other non-current liabilities	2,364
Total liabilities	$	87,788

Total fair value of consideration transferred	$	418,849
Less: fair value of net acquired identifiable assets and liabilities	386,647
Goodwill	$	32,202

The net assets were recorded at their estimated fair value. In valuing acquired assets and liabilities, fair value estimates were based primarily on future expected cash flows, market rate assumptions for contractual obligations, and appropriate discount rates.

The preliminary fair value of finished goods inventory utilizes a sales comparison approach which estimates the selling price of the inventory in completed condition less costs of disposal and a reasonable profit allowance for the selling effort.

As part of the Merger, the Company acquired the product rights to YUTIQ and ILUVIEN. The preliminary fair value of the acquired intangible assets was determined using an income approach, and more specifically, the multi-period excess earnings methodology.

The identifiable intangible assets acquired are amortized on a straight-line basis over their estimated useful lives. The following table summarizes the estimated fair value of identifiable intangible assets acquired and their remaining amortization period (in years):


	Fair Value (in thousands)		Useful Life
ILUVIEN	$	230,000	12
YUTIQ	$	170,000	12

The estimated deferred tax liability, recognized based on the estimated tax impact of the differences between the financial reporting and tax bases of the assets and liabilities acquired, is included in Deferred tax assets, net of deferred tax liabilities and valuation allowance in the consolidated balance sheet as of September 30, 2024.

Goodwill is calculated as the difference between the fair value of the preliminary aggregate purchase consideration and the values assigned to the identifiable tangible and intangible assets acquired and liabilities assumed. Goodwill represents the workforce acquired, as well as future operating efficiencies and cost savings. The actual amount of goodwill will depend upon the final determination of the fair value of the assets acquired and liabilities assumed and may differ materially from this preliminary determination. Goodwill established as a result of the acquisition is tax deductible in the U.S.

Alimera operations generated approximately $3.9 million of net revenue and recorded a net loss of approximately $(8.1) million from the date of acquisition through September 30, 2024.

Transaction Costs

In conjunction with the acquisition, the Company incurred approximately $12.2 million in transaction costs during the nine months ended September 30, 2024, all of which were recognized as selling, general, and administrative expense in the consolidated statement of operations.

Pro Forma Financial Information (unaudited)

The following unaudited pro forma financial information summarizes the results of operations for the periods indicated as if the Acquisition had been completed as of January 1, 2023.


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2024		2023		2024		2023
Net revenues	$	162,700	$	155,193	$	488,180	$	409,610
Net (loss) income	$	(18,749)	$	2,327	$	(17,754)	$	(44,164)

The unaudited pro forma financial information includes, where applicable, adjustments for (i) the amortization of the inventory step-up, (ii) additional amortization expense related to acquired intangible assets, (iii) transaction costs and other one-time non-recurring costs, (iv) additional interest expense for borrowings related to the Acquisition, and (v) associated tax-related impacts of adjustments. These pro forma adjustments are based on the available information as of the date hereof and upon assumptions that the Company believes are reasonable to reflect the impact of the Acquisition with the Company's historical financial information on a pro forma basis. Adjustments do not include costs related to integration activities, cost savings or synergies that have been or may be achieved by the combined business.

INVENTORIES

9 Months Ended

Sep. 30, 2024

Inventory Disclosure [Abstract]

INVENTORIES

Inventories consist of the following as of:


(in thousands)	September 30, 2024		December 31, 2023
Raw materials	$	67,228	$	62,237
Packaging materials	10,522		9,617
Work-in-progress	4,144		3,144
Finished goods	66,148		36,198
Inventories	$	148,042	$	111,196

Note, the Finished goods include the inventory step-up from the acquisition of Alimera of approximately $11.7 million (represents net step-up after amortization).

Vendor Concentration

Raw materials are sourced for products, including active pharmaceutical ingredients (“API”), from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the cost and time required to validate a second source of supply. As a result, the Company is dependent upon our current vendors to reliably supply the API required for on-going product manufacturing. During the three months ended September 30, 2024, no single vendor represented more than 10% of our raw material inventory purchases. During the nine months ended September 30, 2024, 17%, of our raw material purchases were from one supplier. During the three and nine months ended September 30, 2023, no single vendor represented more than 10% of our raw material inventory purchases.

RESTRUCTURING CANADA OPERATIONS	9 Months Ended
RESTRUCTURING CANADA OPERATIONS	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
RESTRUCTURING CANADA OPERATIONS	RESTRUCTURING CANADA OPERATIONS On March 31, 2023 the Company ceased operations at the Oakville, Ontario, Canada manufacturing plant. This action was part of ongoing initiatives to capture operational synergies following the acquisition of Novitium in November 2021. ANI has fully completed the transition of the products manufactured or packaged in Oakville to one of the Company’s three U.S. based manufacturing sites. There were no restructuring activities recorded in the three or nine months ended September 30, 2024 and as of September 30, 2024, there was no severance or other employee benefits accrued on the unaudited interim condensed consolidated balance sheet. There were no restructuring activities recognized in the three months ended September 30, 2023. For the nine months ended September 30, 2023, restructuring activities resulted in expenses of $1.1 million. This included $0.2 million of severance and other employee benefit costs and $0.7 million of accelerated depreciation costs and $0.2 million for other miscellaneous costs. In conjunction with the exit of the Canadian facility, the Company determined that the land and building at the Oakville, Ontario, Canada plant (the “Property”) will be sold together and met the criteria to be classified as held for sale as of September 30, 2023. The land and building had a net carrying value of approximately $8.0 million, which was presented as assets held for sale on the accompanying condensed consolidated balance sheet at December 31, 2023. These assets were part of the Generics, Established Brands, and Other segment. As of September 30, 2024 these assets were sold. On February 15, 2024, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement (the “Agreement”) with 1540700 Ontario Limited (“Buyer”) for the sale of the Property for a total purchase price of $19.2 million Canadian Dollars, or approximately $14.2 million, based on the exchange rate at closing. On March 28, 2024 the Company completed the sale of the Property. After payment of commissions, real estate taxes, and other related costs of approximately $0.7 million, the Company received a net proceeds of approximately $13.5 million at closing. The gain on the sale of the Property was approximately $5.3 million, recorded in the unaudited interim condensed consolidated statements of operations for the nine months ended September 30, 2024.